

# Substrate-binding Sites of UBR1, the Ubiquitin Ligase of the N-end Rule Pathway\*

Received for publication, April 3, 2008, and in revised form, May 19, 2008. Published, JBC Papers in Press, June 19, 2008, DOI 10.1074/jbc.M802583200

Zanxian Xia<sup>†1</sup>, Ailsa Webster<sup>§</sup>, Fangyong Du<sup>¶</sup>, Konstantin Piatkov<sup>‡</sup>, Michel Ghislain<sup>||</sup>, and Alexander Varshavsky<sup>‡2</sup>

From the <sup>†</sup>Division of Biology, California Institute of Technology, Pasadena, California 91125, <sup>§</sup>Celltech R&D, 216 Bath Road, Slough SL1 4EN, United Kingdom, the <sup>¶</sup>Department of Microbial Pathogenesis, Yale University, New Haven, Connecticut 06536-0812, and <sup>||</sup>Group of Physiological Biochemistry, University of Louvain, Croix du Sud 5/15, B-1348 Louvain-la-Neuve, Belgium

Substrates of a ubiquitin-dependent proteolytic system called the N-end rule pathway include proteins with destabilizing N-terminal residues. N-recognins, the pathway's ubiquitin ligases, contain three substrate-binding sites. The type-1 site is specific for basic N-terminal residues (Arg, Lys, and His). The type-2 site is specific for bulky hydrophobic N-terminal residues (Trp, Phe, Tyr, Leu, and Ile). We show here that the type-1/2 sites of UBR1, the sole N-recognin of the yeast *Saccharomyces cerevisiae*, are located in the first ~700 residues of the 1,950-residue UBR1. These sites are distinct in that they can be selectively inactivated by mutations, identified through a genetic screen. Mutations inactivating the type-1 site are in the previously delineated ~70-residue UBR motif characteristic of N-recognins. Fluorescence polarization and surface plasmon resonance were used to determine that UBR1 binds, with a  $K_d$  of ~1  $\mu$ M, to either type-1 or type-2 destabilizing N-terminal residues of reporter peptides but does not bind to a stabilizing N-terminal residue such as Gly. A third substrate-binding site of UBR1 targets an internal degron of CUP9, a transcriptional repressor of peptide import. We show that the previously demonstrated *in vivo* dependence of CUP9 ubiquitylation on the binding of cognate dipeptides to the type-1/2 sites of UBR1 can be reconstituted in a completely defined *in vitro* system. We also found that purified UBR1 and CUP9 interact nonspecifically and that specific binding (which involves, in particular, the binding by cognate dipeptides to the UBR1 type-1/2 sites) can be restored either by a chaperone such as EF1A or through macromolecular crowding.

The N-end rule relates the *in vivo* half-life of a protein to the identity of its N-terminal residue. The ubiquitin (Ub)<sup>3</sup>-depend-

ent N-end rule pathway recognizes several kinds of degradation signals (degrons), including a set called N-degrons (Fig. 1A) (1–9). Although prokaryotes lack the Ub system, they still contain the N-end rule pathway, albeit Ub-independent versions of it (10–18). In eukaryotes, an N-degron consists of three determinants: a destabilizing N-terminal residue of a protein substrate, one (or more) of its internal Lys residues (the site of formation of a poly-Ub chain), and a conformationally flexible region in a vicinity of this residue (1, 19–23). The N-end rule has a hierarchical structure (Fig. 1A). In eukaryotes, N-terminal Asn and Gln are tertiary destabilizing residues in that they function through their enzymatic deamidation, to yield the secondary destabilizing N-terminal residues Asp and Glu (24, 25). The destabilizing activity of N-terminal Asp and Glu requires their conjugation to Arg, one of the primary destabilizing residues, by Arg-tRNA-protein transferase (arginyl-transferase or R-transferase) (5–7, 26, 27). In mammals and other eukaryotes that produce nitric oxide (NO), the set of arginylated residues contains not only Asp and Glu but also N-terminal Cys (28), which is arginylated after its oxidation to Cys-sulfinate or Cys-sulfonate (27). The *in vivo* oxidation of N-terminal Cys requires NO, as well as oxygen (O<sub>2</sub>) or its derivatives (Fig. 1A) (6, 7, 29). The N-end rule pathway is thus a sensor of NO, through the ability of this pathway to destroy proteins with N-terminal Cys, at rates controlled by NO, O<sub>2</sub>, and their derivatives.

E3 Ub ligases of the N-end rule pathway, called N-recognins (1, 8, 29–37), recognize (bind to) primary destabilizing N-terminal residues, including Arg (Fig. 1A). (The term “Ub ligase” denotes either an E2-E3 holoenzyme or its E3 component.) At least four N-recognins, including UBR1, mediate the N-end rule pathway in mammals (30–33, 36). The known N-recognins share an ~70-residue motif called the UBR box. Mouse UBR1 and UBR2 are sequelogous (similar in sequence) 200-kDa RING-type E3 Ub ligases that are 47% identical. Several other UBR-containing N-recognins, either confirmed or putative ones, are HECT-type or SCF-type E3 Ub ligases that share the UBR motif with the RING-type UBR1/UBR2 but are largely nonsequelogenous to them otherwise (29–33). (A note on terminology: “sequelog” and “spalog” denote, respectively, a sequence that is similar, to a specified extent, to another sequence, and a three-dimensional structure that is similar, to a

specific for N-terminal Asp, Glu, and (oxidized) Cys; NO, nitric oxide; FP, fluorescence polarization; SPR, surface plasmon resonance;  $\beta$ gal,  $\beta$ -galactosidase; ORF, open reading frame; PBS, phosphate-buffered saline; HPLC, high pressure liquid chromatography; GST, glutathione S-transferase; py, polyoma; Leu-Eth, L-leucyl-L-ethionine; nt, nucleotide.

\* This work was supported, in whole or in part, by National Institutes of Health Grants DK39520 and GM31530 (to A. V.). This work was also supported by the Ellison Medical Foundation and the Sandler Program for Asthma Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> Present address: Center for Stem Cell and Regenerative Medicine, University of Southern California, Los Angeles, CA 90033.

<sup>2</sup> To whom correspondence should be addressed. Tel.: 626-395-3785; Fax: 626-440-9821; E-mail: avarsh@caltech.edu.

<sup>3</sup> The abbreviations used are: Ub, ubiquitin; E1, ubiquitin-activating enzyme; E2, ubiquitin-conjugating enzyme (or ubiquitin carrier protein); E3, ubiquitin-protein isopeptide ligase; R-transferase, arginyl-tRNA-protein transferase; L/F<sup>K,R</sup>-transferase, Leu/Phe-tRNA-protein transferase specific for N-terminal Lys or Arg; L<sup>D,E</sup>-transferase, Leu-tRNA-protein transferase spe-

specified extent, to another three-dimensional structure (38). Besides their usefulness as separate terms for sequence and spatial similarities, the rigor-conferring advantage of sequelog and spallog is their *evolutionary neutrality*, in contrast to interpretation-laden terms such as “homolog,” “ortholog,” and “paralog.” The latter terms are compatible with the sequelog/spallog terminology and can be used to convey understanding about functions and common descent, if this (additional) information is available (38).

The N-end rule pathway of *S. cerevisiae* is mediated by a single N-recognin, UBR1, a 225-kDa sequelog of mammalian UBR1 and UBR2 (Fig. 1, A and C) (8, 9). *Saccharomyces cerevisiae* UBR1 (Fig. 1C) contains at least three substrate-binding sites. The type-1 site is specific for basic N-terminal residues of protein substrates (Arg, Lys, and His), whereas the type-2 site is specific for bulky hydrophobic N-terminal residues (Trp, Phe, Tyr, Leu, and Ile). The third binding site of UBR1 targets proteins through their internal (non-N-terminal) degron, and is allosterically “activated” through a conformational change that is caused by the binding of short peptides to the two other binding sites of UBR1, type-1 and type-2. The known substrate of the third binding site of UBR1 is CUP9 (8, 39, 40), a transcriptional repressor whose regulon includes *PTR2* (41), a gene encoding transporter of di- and tripeptides. The reversal of UBR1 autoinhibition by imported peptides accelerates the UBR1-dependent ubiquitylation of CUP9, leads to its faster degradation, and thereby causes a derepression of *PTR2*. The resulting positive feedback circuit allows *S. cerevisiae* to detect the presence of extracellular peptides and to react by increasing their uptake (8, 40). ClpS, a 12-kDa prokaryotic N-recognin, is an “adaptor” protein that mediates the (Ub-independent) targeting of N-end rule substrates in bacteria (13–15). ClpS recognizes type-2 (bulky hydrophobic) N-terminal residues and contains a region of sequelogy to the 225-kDa yeast UBR1, near its UBR box (2, 13, 42). This similarity and other common features of eukaryotic and prokaryotic N-end rule pathways (1, 2, 29) suggest that at least some N-degrons, N-recognins, and relevant “downstream” proteases had evolved before the split between eukaryotes and prokaryotes.

The functions of the N-end rule pathway include: (i) the sensing of heme, through inhibition of the ATE1 R-transferase, in both yeast and mammals, by heme ( $\text{Fe}^{3+}$ -heme), which also inhibits N-recognins, the latter at least in yeast (4) (Fig. 1A); (ii) the sensing of NO and oxygen and the resulting control of signaling by transmembrane receptors through the conditional, NO/O<sub>2</sub>-mediated degradation of G-protein regulators RGS4, RGS5, and RGS16 (6, 7); (iii) regulation of import of short peptides through the degradation, modulated by peptides, of CUP9, the repressor of import (8, 40); (iv) fidelity of chromosome segregation through degradation of a separate-produced cohesin fragment (43); (v) regulation of apoptosis through degradation of a caspase-processed inhibitor of apoptosis (44, 45); (vi) a multitude of processes mediated by the transcription factor c-FOS, a conditional substrate of the N-end rule pathway (46); (vii) regulation of the human immunodeficiency virus replication cycle through degradation of human immunodeficiency virus integrase (47); and (viii) regulation of meiosis, spermatogen-

esis, neurogenesis, and cardiovascular development in mammals (6, 7, 27, 31, 33) and leaf senescence in plants (48). Mutations in human UBR1 (Fig. 1A) (29, 32, 33) are the cause of Johansson-Blizzard syndrome, which includes mental retardation, physical malformations, and severe pancreatitis (49). The abnormalities of *UBR1*<sup>-/-</sup> mice (30) include pancreatic insufficiency (49), a less severe counterpart of this defect in human Johansson-Blizzard syndrome (*UBR1*<sup>-/-</sup>) patients.

In this study, we used a genetic screen to probe the type-1 and type-2 substrate-binding sites of *S. cerevisiae* UBR1. This analysis demonstrated a modular organization of these sites, which could be selectively inactivated by specific mutations. We also characterized physical interactions between UBR1 and CUP9 that involve the internal (non-N-terminal) degron of CUP9, and we employed a completely defined *in vitro* system to probe the conditional (modulated by dipeptides) polyubiquitylation of CUP9 by the UBR1-RAD6 Ub ligase. In addition, we used both fluorescence polarization (FP) and surface plasmon resonance (SPR) to determine the affinities of purified UBR1 for specific N-terminal residues of model peptides. The results indicated, among other things, that at least the bulk of the observed *in vivo* specificity of UBR1 for N-end rule substrates (1, 2, 29) (Fig. 1, A and C) stems from differences in the physical affinity of UBR1 for destabilizing *versus* stabilizing N-terminal residues in the N-end rule.

### EXPERIMENTAL PROCEDURES

**Yeast Strains, Media, and Genetic Techniques**—Synthetic yeast media (50) contained 0.67% yeast nitrogen base without amino acids (Difco) and either 2% glucose (SD medium) or 2% galactose (SG medium). Synthetic media lacking appropriate nutrients were used to select for (and maintain) specific plasmids. Cells were also grown in rich medium (YPD) (51). The *S. cerevisiae* strains were YPH500 (*MAT $\alpha$  ura3-52 lys2-801 ade2-101 his3- $\Delta$ 200 trp1- $\Delta$ 63 his3- $\Delta$ 200 leu2- $\Delta$ 1*), JD52 (*MAT $\alpha$  trp1- $\Delta$ 63 ura3-52 his3- $\Delta$ 200 leu2-3,112 lys2-801*), JD55 (*MAT $\alpha$  ubr1 $\Delta$ ::HIS3 trp1- $\Delta$ 63 ura3-52 his3- $\Delta$ 200 leu2-3,112 lys2-801*) (52), SC295 (*MAT $\alpha$  GAL4 GAL80 ura3-52, leu2-3,112 reg1-501 gal1 pep4-3*) (8), and PJ69-4A (*MAT $\alpha$  trp1-901 leu2-3,112 ura3-52 his3-200 gal4 $\Delta$  gal80 $\Delta$  GAL2-ADE2 LYS2::GAL1-HIS3 met2::GAL7-lacZ*). The medium for dipeptide import assays was methionine-lacking SD containing allantoin (1 mg/ml) and the toxic dipeptide L-leucyl-L-ethionine (Leu-Eth; 37  $\mu$ M) (39). To induce the P<sub>CUP1</sub> promoter, CuSO<sub>4</sub> was added to a final concentration of 0.1 mM (52). The XGal colony overlay assay was performed using 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside (XGal) at 0.1 mg/ml, as described (53). Transformation of *S. cerevisiae* was carried out using the lithium acetate method (50).

**Reporter Plasmids**—Five sets of reporter plasmids were used. Details of their construction are available upon request. pUB23-X high copy plasmids expressed Ub-X-e<sup>K</sup>- $\beta$ -galactosidase fusions (denoted below as Ub-X- $\beta$ gal) from the galactose-inducible P<sub>GAL1</sub> promoter (19, 54). pBAX plasmids expressed Ub-X-e<sup>K</sup>-ha-URA3 fusions (X = Arg or Leu), denoted below as Ub-X-URA3. The largely cotranslational deubiquitylation of these Ub fusions (55) yielded the corresponding X- $\beta$ gal and

X-URA3 reporter proteins. pBAX plasmids were constructed from pBAM, a pRS314-based low copy plasmid expressing Ub-Met-e<sup>K</sup>-ha-URA3 (tagged with the ha epitope (50)) from the P<sub>CUP1</sub> promoter (56). The term e<sup>K</sup> (extension (e) bearing lysines (K)) denotes an ~40-residue, *Escherichia coli* Lac repressor-derived sequence (21, 54, 56). pDSRULB was constructed by subcloning the 5.4-kb *Sma*I fragment from pUB23-L (encoding Ub-Leu-βgal) into the *Sma*I site of pBAR, encoding Ub-Arg-URA3. The resulting low copy TRP1-marked pRS314 plasmid expressed Ub-Arg-URA3 from the P<sub>CUP1</sub> promoter and Ub-Leu-βgal from the P<sub>GAL1</sub> promoter. The similarly constructed pDSLURB expressed Ub-Leu-URA3 and Ub-Arg-βgal. The UPR (Ub/protein/reference) plasmids (21, 40, 57) for expression in *S. cerevisiae*, termed pBAXUPR, were based on the low copy pRS314 vector (58) and were constructed using PCR. A pBAXUPR plasmid expressed DHFRha-Ub<sup>R48</sup>-X-e<sup>K</sup>-ha-URA3 (denoted below as DHFR-Ub-X-URA3) from the P<sub>CUP1</sub> promoter (where X = Met, Arg, Leu, Glu, Lys, His, Ile, Phe, Tyr, or Trp). The analogous UPR-based plasmids, termed pXβgalUPR, expressed DHFRha-Ub<sup>R48</sup>-X-e<sup>K</sup>-βgal (X = Met, Arg, or Leu), denoted as DHFR-Ub-X-βgal. pXβgalUPR were constructed by cutting an appropriate pBAXUPR plasmid with BamHI and *Sma*I, recovering the vector-containing fragment, and ligating it to the 3.8-kb βgal-encoding fragment produced from pUB23-M using BamHI and *Sma*I.

**UBR1 Plasmids**—*S. cerevisiae* UBR1 plasmids encoding wild-type or mutated UBR1 included pRBUBR1, pRB208, pFLAGUBR1SBX, pFLAGNT1UBR1, pUBR1NT1140FLAG, p209NTUBR1FLAG, p454NTUBR1FLAG, p710NTUBR1FLAG, p866NTUBR1FLAG, and p1002NTUBR1FLAG. Details of construction are available upon request. UBR1 alleles were expressed from the P<sub>ADHI</sub> promoter of the high copy LEU2-marked YEplac181 vector (59) in SC295, a protease-deficient *S. cerevisiae* strain. UBR1 and its derivatives that were encoded by the above plasmids carried either the ha epitope (pRBUBR1 and pRB208) or the FLAG epitope. pRB208 and pRBUBR1 (a derivative of pRB208) encoded full-length, C-terminally ha-tagged *S. cerevisiae* UBR1 (UBR1<sup>ha</sup>). pFLAGUBR1SBX encoded <sup>f</sup>UBR1, the N-terminally FLAG-tagged full-length UBR1. pFLAGNT1UBR1 encoded <sup>f</sup>UBR1<sup>1-717</sup>, the N-terminally FLAG-tagged C-terminally truncated variant of UBR1. The design and expression of <sup>f</sup>UBR1 and <sup>f</sup>UBR1<sup>1-717</sup> were described (8). The plasmids p209NTUBR1FLAG, p454NTUBR1FLAG, p710NTUBR1FLAG, p866NTUBR1FLAG, and p1002NTUBR1FLAG, which encoded, respectively, UBR1<sup>209-1140f</sup>, UBR1<sup>454-1140f</sup>, UBR1<sup>710-1140f</sup>, UBR1<sup>866-1140f</sup>, and UBR1<sup>1002-1140f</sup>, were derivatives of pUBR1NT1140FLAG (8), a high copy plasmid that expressed C-terminally FLAG-tagged UBR1<sup>1-1140f</sup> from the yeast P<sub>ADHI</sub> promoter. The FLAG tag was located at the C terminus of the UBR1 derivatives except for the full-length <sup>f</sup>UBR1 and <sup>f</sup>UBR1<sup>1-717</sup>. UBR1 test proteins remained intact in yeast extracts that were prepared and incubated as described previously (8).

**Expression and Purification of X-SCC1-GST**—A set of three pTYB12-X-SCC1-GST plasmids, which expressed Intein-CBD-X-SCC1-GST fusions (X = Arg, Leu, or Met), was employed for glutathione S-transferase (GST) pull-down assays. Details of construction are available upon request. A specific pTYB12-X-SCC1-GST plasmid was cotransformed into *E. coli* BL21(DE3) together

with pRI952, which expressed tRNAs for the codons AGG, AGA, and AUA that are rare in *E. coli* (60). A fresh *E. coli* colony was inoculated into LB medium (600 ml) containing ampicillin (0.1 mg/ml) and chloramphenicol (25 μg/ml), followed by growth at 37 °C until A<sub>600</sub> of 0.5–0.8. Isopropyl β-D-thiogalactopyranoside was then added to the final concentration of 0.4 mM, followed by a 10-h incubation, with shaking, at 18 °C. The cells were centrifuged at 5,000 × g for 10 min at 4 °C, washed once with phosphate-buffered saline (PBS), and frozen in liquid N<sub>2</sub>. For isolation of proteins, the cell pellet was thawed at 0 °C and then resuspended in lysis buffer (0.1% Triton X-100, 0.5 M NaCl, 20 mM Tris-HCl, pH 8.5) containing protease inhibitor mixture (Roche Applied Science) (6 ml of buffer per 1 g of pellet), and cells were disrupted by sonication on ice. The suspension was centrifuged at 13,000 × g for 30 min. The supernatant was loaded onto a pre-equilibrated chitin column (10-ml bed volume), at a rate not higher than 0.5 ml/min, and washed with 200 ml of column buffer (0.5 M NaCl, 1 mM EDTA, 20 mM Tris-HCl, pH 8.5), at 1 ml/min. The column was then flushed quickly with 30 ml of freshly prepared cleavage buffer (column buffer containing 40 mM dithiothreitol); the flow was stopped, and the column was incubated at 23 °C for 16 h. X-SCC1-GST proteins were eluted with 30 ml of column buffer, concentrated with Centrplus (Millipore, Billerica, MA), and dialyzed against column buffer at 4 °C. The resulting samples were stored in small aliquots at –80 °C. The presence of desired N-terminal residues in the purified X-SCC1-GST proteins was verified using N-terminal sequencing by Edman degradation. GST-CUP9 was expressed and purified as described (8).

**Expression and Purification of <sup>f</sup>UBR1 and UBR1<sup>1-1140f</sup>**—To express and purify the C-terminally FLAG-tagged UBR1<sup>1-1140f</sup>, *S. cerevisiae* (SC295) carrying pUBR1NT1140FLAG was grown to A<sub>600</sub> of ~1.5, and the cells were harvested by centrifugation. The lysate was prepared as described (8), using lysis buffer (10% glycerol, 0.05% Nonidet P-40, 0.2 M KCl, 50 mM HEPES, pH 7.1), followed by the addition of anti-FLAG beads (Sigma), 1-h incubation with rocking, washing of the beads with lysis buffer, and the elution of UBR1<sup>1-1140f</sup> with the FLAG peptide at 0.2 mg/ml in lysis buffer lacking Nonidet P-40. The expression and purification of N-terminally FLAG-tagged full-length UBR1 (<sup>f</sup>UBR1) were similar to that of UBR1<sup>1-1140f</sup>, with modifications. A single colony of SC295 *S. cerevisiae* transformed with the pFLAGUBR1SBX was inoculated into 20 ml of yeast SD medium and grown at 30 °C to A<sub>600</sub> of ~1. The 20-ml culture was re-inoculated into 2 liters of SD medium and grown to A<sub>600</sub> of ~1, followed by the addition of equal volume of yeast YPD medium. The cells were grown for ~3 more generations, until A<sub>600</sub> of ~4, harvested by centrifugation, washed once with cold 1× PBS, and frozen in liquid N<sub>2</sub>. Other procedures, including purification, were identical to those with UBR1<sup>1-1140f</sup>. Concentrations of purified <sup>f</sup>UBR1 and UBR1<sup>1-1140f</sup> were determined using the Protein Assay reagent (Bio-Rad). Samples of purified <sup>f</sup>UBR1 and UBR1<sup>1-1140f</sup> were frozen in liquid N<sub>2</sub> and stored at –80 °C.

**GST Pull-down Assays and Related Procedures**—An SCC1-based GST fusion protein (~2 μg) (see above) was diluted to 0.3 ml in PBS-based buffer (10% glycerol, 1% Triton X-100, 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.4 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.4) and incubated with 20 μl of glutathione-Sepharose-4B beads (Amersham Biosciences) for 30 min at

## UBR1 Ubiquitin Ligase

4 °C. The beads were washed once with 0.5 ml of PBS-based buffer and twice with 0.5 ml of GST pulldown buffer (10% glycerol, 0.05% Nonidet P-40, 50 mM NaCl, 50 mM HEPES, pH 7.6). The washed beads, in 0.15 ml of the binding buffer, were incubated at 4 °C for 1 h with 0.1 ml of *S. cerevisiae* extract (~5 mg/ml total protein) containing either <sup>f</sup>UBR1 (N-terminally FLAG-tagged UBR1) or its truncated derivatives (see above) at the same concentration. These assays were performed in either the presence or absence of specific amino acids or amino acid derivatives, including dipeptides (Sigma), at concentrations indicated in figure legends. Binding assays also contained ovalbumin (Sigma; at 0.1 mg/ml, unless not stated otherwise), protease inhibitor mixture (Sigma), and 50 μM bestatin (Sigma). The beads were washed twice with 0.2 ml of the binding buffer either containing or lacking specific dipeptides, depending on whether a binding assay contained them. Washed beads were resuspended in 30 μl of SDS-PAGE loading buffer and heated at 95 °C for 4 min, and 15-μl samples were subjected to SDS-10% PAGE, followed by immunoblotting with anti-FLAG M2 antibody (Sigma).

CUP9-based GST pulldown assays with <sup>f</sup>UBR1 were carried out similarly except for the following: the total volume was 0.26 ml, with 1 μl of purified <sup>f</sup>UBR1 (0.4 mg/ml), either in binding buffer (10% glycerol, 0.05% Nonidet P-40, 50 mM NaCl, 50 mM HEPES, pH 7.5), or in binding buffer supplemented with 60 μl of *S. cerevisiae* "empty" extract (no FLAG-tagged UBR1), or in GST-binding buffer containing ovalbumin (at 10 mg/ml); or in 0.2 ml of binding buffer supplemented with 60 μl of *S. cerevisiae* extract containing <sup>f</sup>UBR1. With UBR1<sup>1-1140f</sup>, the assay was performed similarly, except that the reaction volume was 0.23 ml (0.2 ml of binding buffer plus 30 μl of extract from *S. cerevisiae* that produced UBR1<sup>1-1140f</sup>) or, alternatively, the same (30 μl) volume but containing 1 μl of purified UBR1<sup>1-1140f</sup> (at 0.2 mg/ml), and ovalbumin at 50 mg/ml, as described in figure legends.

In another binding assay, we employed <sup>py</sup>CUP9his<sub>6</sub>, a purified (after overexpression in *E. coli*), GST-lacking, full-length CUP9 bearing the N-terminal "polyoma" (py) epitope tag that could be detected with a monoclonal antibody (61) (AK6967; a gift from Dr. S. Stevens and Dr. J. Abelson (Caltech)). 0.25 ml of <sup>f</sup>UBR1-containing yeast extract (~5 mg/ml total protein) was incubated with 15 μl of anti-FLAG M2 affinity beads (Sigma) at 4 °C for 1 h. The beads were then washed with 1 ml of lysis buffer (0.2 M KCl, 50 mM HEPES, pH 7.5, 10% glycerol, 0.05% Nonidet P-40), twice with 1 ml of lysis buffer containing 0.6 M KCl, once with 1 ml of lysis buffer, and twice with 0.5 ml of GST pulldown buffer (see above). The washed beads were incubated in 0.2 ml of GST pulldown buffer at 4 °C for 1 h with 2 or 4 μl of purified <sup>py</sup>CUP9his<sub>6</sub> (0.8 mg/ml), either alone or in the presence of <sup>f</sup>UBR1-lacking yeast extract (60 μl; 5 mg/ml total protein). Some of assay samples also contained Arg-Ala and Leu-Ala dipeptides, at 1 mM each (Sigma). In addition, all assay samples contained 0.1 mg/ml ovalbumin, a protease inhibitor mixture (Sigma) and 50 μM bestatin (Sigma). Incubated samples were processed by washing anti-FLAG affinity beads twice with 0.2 ml of GST pulldown buffer (containing dipeptides at the same concentrations as in incubated samples), and the

bound proteins were eluted with 0.5 mg/ml FLAG peptide in GST pulldown buffer, followed by SDS-10% PAGE and immunoblotting with antibody to the Py epitope.

*X-Peptide Pulldown Assays*—Procedures were similar to those described previously (8, 29, 31, 32). Residues 2–9 of synthetic 12-mer *X*-peptides (*X*-Ile-Phe-Ser-Thr-Asp-Thr-Gly-Pro-Gly-Gly-Cys, where *X* = Arg, Phe, or Gly), were derived from residues 2–9 of Sindbis virus polymerase nsP4, a previously identified N-end rule substrate (1, 62). Hence the acronym for a specific *X*-peptide, "*X*-nsP4pep." 20 μl (5 mg/ml total protein) of *S. cerevisiae* extract containing (overexpressed) *S. cerevisiae* UBR1 or its fragments (indicated above) was diluted into 0.2 ml of binding buffer (10% glycerol, 0.05% Nonidet P-40, 0.2 M KCl, 50 mM HEPES, pH 7.5) in the presence of 0.1 mg/ml ovalbumin, protease inhibitor mixture (Sigma), and 50 μM bestatin. The samples were incubated with 5 μl (packed volume) of a carrier-linked *X*-nsP4pep for 1 h at 4 °C. The beads were pelleted by a brief centrifugation and then washed with 0.3 ml of binding buffer three times. The beads were then resuspended in 30 μl of SDS-PAGE sample buffer and heated at 95 °C for 4 min, followed by a brief centrifugation in a microcentrifuge, SDS-10% PAGE of 3-μl samples of supernatants, and detection of FLAG-tagged UBR1 or its fragments by immunoblotting with anti-FLAG M2 antibody.

*Labeling, Purification, and Analysis of X-Peptides*—The above peptides were also employed as probes in the fluorescence polarization (FP) assay. To conjugate Alexa Fluor-488-C5 maleimide (Invitrogen) to C-terminal Cys of an *X*-nsP4pep, this dye (0.6 μmol in 90 μl of dimethyl sulfoxide (DMSO)) was added to 0.4 μmol of *X*-nsP4pep in 90 μl of DMSO, followed by incubation at room temperature for 4 h. Alexa-labeled *X*-peptides were purified by HPLC, using analytical scale VYDAC column (C18 reverse phase), followed by verification of purified peptides by mass spectrometry. The concentration of labeled *X*-peptides was measured by using either BCA reagent (Pierce) or N-terminal sequencing by Edman degradation, or amino acid analysis, with similar results.

*Fluorescence Polarization Assay*—The concentration of fluorescently labeled *X*-peptides was kept at 10 nM. Before carrying out the FP assay, we ascertained that the levels of background fluorescence of the binding buffer (10% glycerol, 0.02% Nonidet P-40, 0.2 M KCl, 50 mM HEPES, pH 7.1), of the competitor (unlabeled) dipeptides or *X*-peptides, and of the UBR1<sup>1-1140f</sup> protein (in the same buffer), at their highest concentrations used, were low enough, less than 5% of the fluorescence of a labeled *X*-nsP4pep in the assay. The FP assay (63, 64) was carried out as described in the published protocol ("Fluorescence Polarization: Technical Resource Guide" (PanVera Corp., now a part of Invitrogen)), with the following modifications. Purified UBR1<sup>1-1140f</sup> was serially diluted into ~14 microcentrifuge tubes, covering the range of its concentrations from more than 10-fold below (estimated) dissociation constant (*K<sub>d</sub>*) of UBR1<sup>1-1140f</sup> interactions with a cognate peptide to more than 10-fold above estimated *K<sub>d</sub>*. Identical samples of an Alexa-labeled *X*-nsP4pep were added to each of the above tubes, gently mixed, and incubated at 4 °C for 30 min, in the final volume of 50 μl. FP measurements were carried out using the Analyst AD&HT Assay Detection System (Molecular Devices, Sunny-

vale, CA) and a xenon-arc lamp as a light source, in a standard FP configuration, with filter settings optimized for the excitation wavelength of 485 nm and the emission wavelength of 530 nm. Two fluorescence measurements were collected for each well, with either parallel (S and S) or perpendicular (S and P) polarizers. These data were used to calculate polarization, in millipolarization units (mP), by the Analyst System. The affinities, expressed as  $K_d$  values, were calculated from the above data. Their statistical significance was estimated by nonlinear regression analysis, using Prism (Graphpad, San Diego, CA). FP-based competition assays were carried out similarly, except that concentration of UBR1<sup>1-1140f</sup> was kept constant, and (unlabeled) competitor X-peptides were added to the binding assay. The concentration of UBR1<sup>1-1140f</sup> in competition FP assays was close to the  $K_d$  value ( $\sim 1 \mu\text{M}$ ; see "Results") of the UBR1<sup>1-1140f</sup> interaction with Arg-nsP4pep.

**Surface Plasmon Resonance BIAcore Assay**—The X-peptides Phe-nsP4pep, Arg-nsP4pep, or Gly-nsP4pep were linked, through their C-terminal Cys (see above), to biotin, using EZ-Link PEO-Iodoacetyl Biotin (Pierce), to allow immobilization of peptides onto streptavidin-coated SA sensor chips of BIAcore-2000 (Biacore). Biotin-labeled X-peptides were purified by HPLC, using analytical scale VYDAC column (C18 reverse phase), followed by verification of purified peptides by matrix-assisted laser desorption ionization time-of-flight. The concentration of labeled X-peptides was measured using EZ<sup>TM</sup>-Biotin quantification kit (Pierce). A biotin-containing X-peptide, at  $0.1 \mu\text{M}$  in the running buffer (0.02% Nonidet P-40, 0.2 M KCl, 50 mM HEPES, pH 7.5), was injected over the sensor chip surface at  $10 \mu\text{l min}^{-1}$  at  $25^\circ\text{C}$ , resulting in the surface density for the X-peptide of 30–35 resonance units. Purified UBR1<sup>1-1140f</sup> was serially diluted in running buffer and injected at  $75 \mu\text{l min}^{-1}$  for 80 s at  $25^\circ\text{C}$ . After 5 min, to allow dissociation of the formed complexes, the sensor chip was washed by two 1-min injections of  $2 \text{ M MgCl}_2$  at  $50 \mu\text{l/min}$ . BIAcore readouts were corrected by subtracting readouts from the mock surface (lacking an X-peptide) as well as readouts from a buffer-only (control) injection. Raw data were processed using Scrubber (BioLogic Software, Australia) and CLAMP programs and the 1:1 Langmuir interaction model, with a correction for mass transport (65, 66).

**UBR1-dependent in Vitro Ubiquitylation System**—This completely defined system, consisting exclusively of purified recombinant proteins and small compounds, was described in Ref. 40 and in detail in Ref. 67. Briefly, C-terminally His<sub>6</sub>-tagged *S. cerevisiae* UBA1 (E1, Ub-activating enzyme) was overexpressed in *S. cerevisiae* SC295 and purified using nickel-nitrilotriacetic acid (His<sub>6</sub> affinity) chromatography, immobilized Ub ("covalent" affinity) chromatography, and Superdex-200 gel filtration (68). *S. cerevisiae* RAD6 (UBC2) was overexpressed in *E. coli* and purified by fractionation over DEAE, Mono-Q, and Superdex-75 columns. N-terminally FLAG-tagged *S. cerevisiae* UBR1 (<sup>f</sup>UBR1) was overexpressed in *S. cerevisiae*, as described section above, and was purified by fractionation over immobilized anti-FLAG M2 antibody, immobilized RAD6, and Superdex-200 columns (Fig. 7D). N-terminally FLAG-tagged, C-terminally His<sub>6</sub>-tagged *S. cerevisiae* <sup>f</sup>CUP9his<sub>6</sub> was expressed and labeled with [<sup>35</sup>S]methionine in *E. coli*, followed by purification over nickel-nitrilotriacetic acid and anti-FLAG M2 antibody

columns. Details of these and related procedures are described in Ref. 67. We also employed a similarly produced, labeled, and purified <sup>py</sup>CUP9his<sub>6</sub> with a different N-terminal tag, called polyoma (py) that was bound by a monoclonal antibody (61) (AK6967; a gift from Dr. S. Stevens and Dr. J. Abelson (Caltech)). The *in vitro* ubiquitylation reactions contained the following components:  $7 \mu\text{M}$  Ub,  $50 \text{ nM}$  UBA1,  $50 \text{ nM}$  RAD6,  $50 \text{ nM}$  UBR1,  $550 \text{ nM}$  <sup>35</sup>S-labeled <sup>f</sup>CUP9his<sub>6</sub>,  $25 \text{ mM}$  KCl,  $5 \text{ mM}$  MgCl<sub>2</sub>,  $2 \text{ mM}$  ATP,  $0.1 \text{ mM}$  dithiothreitol,  $25 \text{ mM}$  HEPES, pH 7.5, and ovalbumin (as a carrier protein) at  $0.5 \text{ mg/ml}$ . Pairs of dipeptides were added to final concentrations specified in the legend to Fig. 8. All components except UBA1 were mixed on ice for 10 min; UBA1 was then added and reactions shifted to  $30^\circ\text{C}$ . The reactions were carried out for 10 min and were terminated by adding an equal volume of  $2\times$  SDS-PAGE loading buffer and heating at  $95^\circ\text{C}$  for 5 min, followed by SDS-10% PAGE and autoradiography.

**Genetic Screen for Type-1 and Type-2 UBR1 Mutants**—Fig. 1B describes the design of the screen. Reporter plasmids expressing either Arg-URA3 (a type-1 N-end rule substrate) and Leu-βgal (a type-2 N-end rule substrate) (pDSRULB plasmid) or Leu-URA3 (a type-2 substrate) and Arg-βgal (a type-1 substrate) (pDSLURB plasmid) were transformed into *S. cerevisiae* JD55, a *ubr1Δ* strain. pRUBR1, a high copy plasmid expressing UBR1 from the P<sub>ADH1</sub> promoter, was mutagenized by treatment with  $1 \text{ M}$  hydroxylamine for 1 h at  $75^\circ\text{C}$ . DNA was precipitated with ethanol, redissolved in  $1 \text{ mM}$  EDTA,  $10 \text{ mM}$  Tris-HCl, pH 8.0, and hydroxylamine was removed using G-25 spin-desalting column (Roche Applied Science). Hydroxylamine-treated pRUBR1 was transformed into JD55 (*ubr1Δ*) carrying one of two reporter plasmids, either pDSRULB or pDSLURB. The transformants were plated onto SD(−Ura) plates, and the resulting Ura<sup>+</sup> colonies (cells that were, presumably, impaired in degrading either Arg-URA3 or Leu-URA3) were replica-plated onto galactose-containing SG plates. The colonies on SG plates were stained for βgal using XGal overlay. Most of the colonies in these experiments stained blue. Because the cells of these colonies were selected, in the preceding step, to be impaired in the degradation of one class (type-1 or type-2) of N-end rule substrates, the failure to degrade an X-βgal that belonged to the other class of N-end rule substrates (type-2 or type-1, respectively) meant that the corresponding alleles of UBR1 were defective in degrading both classes of N-end rule substrates. However, some white colonies on XGal were produced as well, with each of the two bi-reporter plasmids, pDSRULB and pDSLURB. The corresponding pRUBR1 plasmids were rescued from these white colonies and were retransformed into the JD55 (*ubr1Δ*) cells carrying other reporter plasmids, either pBAM (Met-URA3), or pBAR (Arg-URA3), or pBAL (Leu-URA3). The resulting transformants were plated onto either SD (+Ura) or SD(−Ura) to verify that the corresponding variants of UBR1 were indeed selectively impaired in the degradation of either type-1 or type-2 N-end rule substrates.

**Mapping Type-1/2 Mutations in UBR1**—Five fragments of *S. cerevisiae* UBR1, from the pRB208 plasmid, were produced using the following restriction endonucleases: fragment I, SmaI-SpeI (nt 1–510 of the UBR1 ORF); fragment II, SpeI-BglII

## UBR1 Ubiquitin Ligase


(nt 510–1,653); fragment III, BglII-Ball (nt 1,653–3,511); fragment IV, Ball-XbaI (nt 3,511–4,515); and fragment V, XbaI-PstI (nt 4,515–beyond the end of ORF). Each of these fragments was replaced, in the non-mutant pRBUBR1, by the corresponding fragments from a rescued and amplified mutant pRB208, yielding five pRBUBR1-derived plasmids for every mutant plasmid. The five plasmids were transformed, separately, into JD55 (*ubr1Δ*) cells carrying either pBAR (Arg-URA3) or pBAL (Leu-URA3), and the transformants were tested for their ability to grow in the absence of uracil. This way we identified the regions of relevant alterations in the *UBR1* ORF. The corresponding fragments were then sequenced to identify the actual alteration(s).

**Pulse-Chase Analysis**—*S. cerevisiae* in liquid SD medium containing 0.1 mM CuSO<sub>4</sub> (*A*<sub>600</sub> 0.5–1) were labeled for 2 min at 30 °C with 0.15 mCi of [<sup>35</sup>S]methionine/cysteine (EXPRESS, PerkinElmer Life Sciences) as described (21, 52). Cells were harvested by centrifugation, resuspended in 0.3 ml of SD medium containing 10 mM L-methionine and 0.5 mg/ml cycloheximide, and incubated further at 30 °C. Samples of 0.1 ml were removed during the incubation and added to microcentrifuge tubes containing 0.5 ml of 0.5-mm glass beads and 0.7 ml of lysis buffer (1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 50 mM Na-HEPES, pH 7.5, and 1× protease inhibitor mixture (Sigma)). The cells were lysed by vortexing with glass beads, followed by immunoprecipitation with anti-ha antibody (Covance, Princeton, NJ), SDS-PAGE, autoradiography, and quantitation (21, 56). Immunoprecipitation of labeled CUP9-FLAG was carried out as described (39).

**β-Galactosidase and Other Assays**—Cells in 5-ml cultures (*A*<sub>600</sub> 0.8–1) were pelleted by centrifugation at 12,000 × *g* for 2 min and lysed with glass beads in 20% glycerol, 1 mM dithiothreitol, 0.1 M Tris-HCl, pH 8, and the activity of βgal was measured in the clarified extract using *o*-nitrophenyl-β-D-galactoside, as described (50, 69). The activity was normalized to the total protein concentration, determined using Bradford assay (Bio-Rad). For growth-dilution assays, *S. cerevisiae* strains were grown under selection for plasmids in SD medium to an *A*<sub>600</sub> of 0.8–1. Cells (1.5 × 10<sup>7</sup>) from each sample were pelleted by centrifugation and resuspended in 1 ml of water. 4-Fold serial dilutions of cell cultures were set up in microtiter plates as described (39), and cell suspensions were transferred to various media using a 48-pin applicator, followed by incubation at 30 °C for ~36 h to assay for growth.

## RESULTS

**UBR1 Mutants That Are Selectively Defective in Targeting Type-1 or Type-2 N-end Rule Substrates**—To locate the regions of *S. cerevisiae* UBR1 that encompass its type-1 and type-2 substrate-binding sites (see Introduction), and to determine whether these apparently distinct sites (1, 28, 69) are sufficiently modular (independent) to be selectively perturbed by mutations, we carried out a screen described in Fig. 1B and “Experimental Procedures.” A plasmid that expressed Arg-URA3 (a type-1 N-end rule substrate) and Leu-βgal (a type-2 N-end rule substrate), or an otherwise identical plasmid that expressed a “converse” set of reporters, Leu-URA3 (a type-2 substrate) and Arg-βgal (a type-1 substrate), were transformed



**FIGURE 1. The N-end rule pathway in the yeast *S. cerevisiae*.** *A*, *S. cerevisiae* N-end rule pathway. N-terminal residues are indicated by single-letter abbreviations for amino acids. Yellow ovals denote the rest of a protein substrate. Hemin (Fe<sup>3+</sup>-heme) has been found to inhibit the arginylation activity of both the *S. cerevisiae* and mouse ATE1-encoded Arg-tRNA-protein transferase (R-transferase) (4). At least in mammalian cells, hemin also induces the proteasome-dependent degradation of R-transferase (4). MetAPs, methionine aminopeptidases. *Separase* refers to the *ESP1*-encoded protease that cleaves, in particular, the SCC1 subunit of cohesin and thereby allows mitosis (86). The resulting C-terminal fragment of SCC1 bears a destabilizing N-terminal residue (Arg in *S. cerevisiae*) and is degraded by the N-end rule pathway, a step that is essential for high fidelity of chromosome segregation (43). The reactions in a shaded rectangle are a part of the N-end rule pathway that is active in eukaryotes (e.g. vertebrates) that produce nitric oxide (NO) (6), but is also relevant to organisms such as *S. cerevisiae*, which lack NO synthases but can produce NO by other routes, and in addition can be influenced by NO from extracellular sources. C\* denotes oxidized Cys, either Cys-sulfinate or Cys-sulfonate, produced in reactions mediated by nitric oxide, oxygen, and their derivatives. Oxidized N-terminal Cys is arginylated by ATE1-encoded isoforms of R-transferase (6, 7). Type-1 and type-2 primary destabilizing N-terminal residues (see Introduction) are recognized by UBR1, the sole N-recognin of *S. cerevisiae* that functions as a holoenzyme containing UBR1 and the E2 enzyme RAD6. Through its third substrate-binding site, UBR1 recognizes internal (non-N-terminal) degrons in substrates (denoted by a larger oval) such as CUP9, a transcriptional repressor of regulon that includes the PTR2 peptide transporter (8, 39, 40). The addition of hemin to *S. cerevisiae* UBR1 *in vitro* (in cell extracts) was found to inhibit the interaction of UBR1 (through its third substrate-binding site) with CUP9 (4). This inhibition was selective in that hemin did not interfere with the binding of primary destabilizing N-terminal residues of peptide reporters to the type-1 or type-2 binding sites of UBR1 (4). *B*, design of a genetic screen to isolate UBR1 mutants with selectively inactivated type-1 or type-2 substrate-binding sites. *C*, locations of mutations in *S. cerevisiae* UBR1 that were found to selectively inactivate either the type-1 site or the type-2 site. The mutant residues are in red. For the names of specific UBR1 domains, see Refs. 9, 29, 32 and the main text.

into *ubr1Δ S. cerevisiae*, which lacked the N-end rule pathway. pRBUBR1, a high copy plasmid expressing UBR1, was mutagenized *in vitro* with hydroxylamine and transformed into

*ubr1Δ* cells carrying one or the other of the double-reporter plasmids (Fig. 1B). By replica-plating transformants on uracil-lacking SD plates, we could identify cells in which an *X-URA3* reporter remained long lived in the presence of pRBUBR1 from the mutagenized pool, as those cells were *Ura*<sup>+</sup>, because of higher steady-state levels of *URA3*. (Both Arg-*URA3* and Leu-*URA3* were long lived in *ubr1Δ* cells but short lived in wild-type cells (1, 70).) *Ura*<sup>+</sup> colonies were then plated on galactose-containing SG plates. The levels of galactose-induced Arg-βgal (in the Leu-*URA3*-expressing plasmid) or Leu-βgal (in the Arg-*URA3*-expressing plasmid) could then be assessed by staining the colonies with XGal. A blue, *i.e.* high-βgal colony (which already proved to be *Ura*<sup>+</sup> at the preceding step of the screen), would imply the presence of a *UBR1* allele that was impaired in degradation of both type-1 and type-2 substrates (Fig. 1B). Most colonies in these experiments stained blue. The rare white colonies on XGal suggested the presence of *UBR1* variants selectively impaired in one but not the other of two substrate-binding sites. The pRBUBR1 plasmids were rescued from these colonies and were retransformed into *ubr1Δ* cells carrying either Met-*URA3* (not an N-end rule substrate and a relatively long lived protein), or Arg-*URA3* (type-1 substrate), or Leu-*URA3* (type-2 substrate). Plating transformants on either SD (+*Ura*) or SD (–*Ura*) plates could verify whether the corresponding variants of *UBR1* were selectively impaired in the degradation of type-1 or type-2 N-end rule substrates (Fig. 1B).


The initial screen involved ~2,000 transformants bearing mutagenized *UBR1*. With each of two reporter plasmids, ~10% of these transformants were *Ura*<sup>+</sup>. Among these, no *UBR1* isolates were found that were unable to confer instability on a type-1 N-end rule substrate (basic N-terminal residues) but retained the activity against a type-2 substrate (hydrophobic N-terminal residues). However, this screen did yield five putative *UBR1* variants of the opposite kind (active against type-1 but not type-2 N-end rule substrates). A more extensive screen, with ~1 × 10<sup>6</sup> transformants, was then carried out exclusively for *UBR1* variants of the former class (active against type-2 but not type-1 substrates). It yielded ~17,000 *Ura*<sup>+</sup> colonies, *i.e.* isolates in which Arg-*URA3* was at least partially stabilized. 20 of these colonies showed low levels of βgal in the XGal assay (*i.e.* they retained degradation of Leu-βgal). The pRBUBR1 plasmids encoding 20 putative type-1-impaired and 5 putative type-2-impaired *UBR1* variants were rescued, and the specificity of their targeting defects was confirmed by re-testing them in *ubr1Δ* cells expressing either Arg-*URA3* and Leu-βgal or Leu-*URA3* and Arg-βgal, using, in particular, pulse-chase and immunoblot assays (data not shown; see also below).

**Identifying Mutations in *UBR1***—The approximate locations of mutations within the 5,850-bp *UBR1* ORF were determined through fragment swapping between wild-type and mutant *UBR1*s, using unique restriction sites to divide *UBR1* into five nonoverlapping fragments (see “Experimental Procedures”). Once localized to a specific fragment, the actual mutation was determined by DNA sequencing. All of the type-1 and type-2 mutations were located in the N-terminal 30% of *UBR1*. Among ~20 type-1 mutant isolates of *UBR1* (those active with type-2 substrates but inactive with type-1 substrates), only 5 different amino acid changes were present, with 18 of the 20 mutations

affecting either Asp<sup>176</sup> or Gly<sup>172</sup> (Fig. 1C). All of recovered type-1 mutations in *UBR1* were missense alterations, one of them a double missense, in two adjacent residues. Specific changes in the type-1 *UBR1* mutants were C145Y/V146M (a double missense; one isolate); G172R (seven isolates); G172E (four isolates); D176N (five isolates); and D176E (two isolates), encompassing an ~30-residue region of *UBR1* (positions 145–176) (Fig. 1C). In contrast to type-1 *UBR1* mutants, all five of the type-2 *UBR1* mutants contained different amino acid alterations; collectively, these (type-2) alterations encompassed a different and larger region of *UBR1* (positions 313–560). Specific type-2 alterations were V313I; D318N; H321Y; P406S; and E560K (Fig. 1C). Together, the identified type-1 and type-2 mutations spanned a 416-residue stretch within the first 560 residues of the 1,950-residue *UBR1* protein.

**Degradation of N-end Rule Substrates in Type-1 or Type-2 *UBR1* Mutants**—Specific type-1 and type-2 *S. cerevisiae* *UBR1* mutants were verified and further characterized by transforming the corresponding *UBR1*-expressing plasmids into JD55 (*ubr1Δ*) *S. cerevisiae* carrying pβgalUPR or pLβgalUPR. The latter are low copy plasmids expressing, respectively, Arg-βgal or Leu-βgal reporter N-end rule substrates. The relative rates of *in vivo* degradation of *X-βgals* were assessed using extensively validated (9, 24) steady-state measurements of βgal activity in whole cell extracts from *ubr1Δ* cells that carried plasmids expressing specific *UBR1* mutants (Fig. 2, A and B). The results confirmed the initial screen-derived data that Arg-βgal was long lived in the presence of type-1 *UBR1* mutants, but was degraded with type-2 *UBR1* mutants. Conversely, Leu-βgal was long lived in the presence of type-2 *UBR1* mutants but short lived with type-1 *UBR1* mutants (Fig. 2, A and B). In addition to steady-state levels of N-end rule substrates (Fig. 2, A and B), their metabolic stability was also assessed by pulse-chase analysis, using the Ub-protein-reference (UPR) technique (21, 57). This method provides a “built-in” (long lived) reference protein as a part of reporter fusion, and thereby increases the accuracy of pulse-chase and analogous assays. In agreement with steady-state data (Fig. 2, A and B), Arg-*URA3* was relatively long lived in type-1 *UBR1* mutants, exemplified by *UBR1*<sup>D176E-1</sup> cells (the superscript suffixes “-1” or “-2” denote the inactivation of, respectively, the type-1 or type-2 substrate-binding sites of *UBR1*). In contrast, Leu-*URA3* was short lived in a type-1 mutant (Fig. 2D and data not shown; see also Fig. 1C). “Conversely,” Leu-*URA3* was relatively long lived in type-2 *UBR1* mutants, exemplified by *UBR1*<sup>P406S-2</sup>, whereas Arg-*URA3* was short lived in the same mutant (Fig. 2D and data not shown; see also Fig. 1C). (Both Arg-*URA3* and Leu-*URA3* were long lived in the absence of *UBR1* (Fig. 2C).)

***UBR1*-dependent Targeting of CUP9 Requires Intact Type-2 Binding Site of *UBR1***—Previous work has shown that the N-end rule pathway controls the import of short peptides (8, 39–41). Specifically, a third substrate-binding site of *S. cerevisiae* *UBR1*, apparently distinct from its two other (type-1 and type-2) binding sites, targets CUP9. The latter is a transcriptional repressor of, among other genes, *PTR2*, which encodes a plasma-membrane transporter that can import di- and tripeptides. *UBR1* targets CUP9 for ubiquitylation and subsequent degradation through a distinct internal (non-N-terminal) degron of CUP9.



**FIGURE 2. Selective inactivation of type-1 versus type-2 substrate-binding sites in UBR1 mutants.** *A*, wild-type UBR1 and its mutant alleles were expressed from low copy plasmids in *S. cerevisiae* JD55 (*ubr1Δ*) cells that also carried a plasmid expressing Arg-βgal (Ub-Arg-βgal) reporter (see "Experimental Procedures"). Measurements of βgal activity in cell extracts were used to compare the rates of X-βgal reporter degradation *in vivo* (9, 21). The values shown are the means of duplicate measurements of three independent transformants. Standard deviations are indicated above the bars. For the locations of indicated mutations in UBR1, see Fig. 1C. *B*, same as in *A* but with cells expressing Leu-βgal (Ub-Leu-βgal). *C*, pulse-chase assays, using a UPR-type construct (21, 57) expressing either Met-URA3ha, or Arg-URA3ha, or Leu-URA3ha in *ubr1Δ* cells (see "Experimental Procedures"). Lane 1, molecular mass marker; their masses, in kDa, are indicated on the left. *D*, same as in *C*, but with *ubr1Δ* cells that expressed either wild-type UBR1, or its type-1 UBR1<sup>D176E-1</sup> mutant, or its type-2 UBR1<sup>P406S-2</sup> mutant. The <sup>35</sup>S-bands of X-URA3ha reporters and the DHFRh-Ub reference protein are indicated.



**FIGURE 3. In vivo effects of mutants in the type-1 or type-2 substrate-binding sites of UBR1.** *A*, toxic-peptide (Leu-Eth) resistance assay (39, 41) (see "Experimental Procedures") with *ubr1Δ* *S. cerevisiae* versus its derivatives that expressed type-1 UBR1 mutants (Fig. 1C). *B*, same as in *A*, but the assay was carried with type-2 UBR1 mutants, and the result with wild-type UBR1 is shown as well (Fig. 1C). See the main text for details.

In wild-type cells, peptides with destabilizing N-terminal residues bind to the type-1 and type-2 binding sites of UBR1 and thereby allosterically activate its otherwise autoinhibited third site for binding to CUP9 (8, 40). This reversal of autoinhibition leads to the targeting of CUP9 by UBR1, to accelerated degradation of CUP9, and thus to the induction of PTR2 expression and peptide import. The resulting positive feedback circuit

allows *S. cerevisiae* to detect the presence of extracellular peptides and to react by increasing their uptake (8, 40). In *ubr1Δ* yeast, CUP9 is a relatively long lived protein ( $t_{1/2} > 50$  min). As a result, the expression of PTR2 transporter is extinguished, making *ubr1Δ* cells incapable of importing peptides and therefore resistant to a toxic dipeptide such as Leu-Eth (39).

We employed the toxic peptide resistance assay to probe *in vivo* aspects of UBR1 mutants identified in this study work. Plasmids expressing type-1 or type-2 mutant alleles of UBR1 were transformed into *ubr1Δ* yeast, and the resulting transformants were streaked onto Leu-Eth (toxic peptide) plates. Growth of cells on such plates indicates that the CUP9 repressor is metabolically stabilized in these cells, resulting in a down-regulation of expression of PTR2 transporter and therefore in hyper-resistance of cells to Leu-Eth. The results showed that CUP9 was stabilized in cells transformed with all of type-2 UBR1 mutants (Fig. 3B), but it was still degraded in cells transformed with four of the five type-1 UBR1 mutants (Fig. 3A). (With the fifth type-1 mutant, UBR1<sup>CV145YM-1</sup> (Fig. 1C), cell growth on Leu-Eth plates was partially retarded relative to *ubr1Δ* strains.) These findings

suggest that the third (CUP9-recognizing) site of UBR1 either structurally overlaps with the type-2 binding site or depends on this site for its function.

**Specificity of UBR1 Interactions with N-end Rule Substrates and X-Peptides**—Our previous work described the use of N-recognin ligands containing the GST moiety linked to the C terminus of a fragment of *S. cerevisiae* SCC1, a subunit of cohesin. This 33-kDa SCC1 fragment, which normally bears N-terminal Arg, is produced in yeast through the conditional cleavage by separate ESP1 and is degraded by the N-end rule pathway (43). Purified X-SCC1-GSTs (X = Arg, Leu, or Met) bearing type-1 (Arg), or type-2 (Leu), or stabilizing (Met) N-terminal residues were linked to glutathione-Sepharose, and the previously characterized (8) GST pulldown assay was carried out with yeast extracts that contained the overexpressed, FLAG-tagged, full-length <sup>f</sup>UBR1 or its derivatives (Fig. 4). Similarly to mouse UBR1 and UBR2 (31), *S. cerevisiae* <sup>f</sup>UBR1 did not bind to Met-SCC1-GST (Fig. 4D, lane 1) but bound to both Leu-SCC1-GST and Arg-SCC1-GST (Fig. 4, A and B, lanes 2). This binding was specific for type-1 versus type-2 N-terminal residues, as the Arg-Ala and Leu-Ala dipeptides selectively

inhibited the binding of corresponding (“alternative”) X-SCC-GST reporters (Fig. 4, A and B). To probe specificity of this inhibition, we tested other small compounds as well. Whereas increasing concentrations of Arg-Ala inhibited the binding of Arg-SCC1-GST to <sup>f</sup>UBR1, neither Ala-Arg, nor an equimolar mixture of the corresponding free amino acids (Arg+Ala), nor Arg methyl ester (Arg-OMe), nor agmatine ((4-aminobutyl)-guanidine), the decarboxylation product of Arg and a putative neurotransmitter (71)) exhibited this effect (Fig. 4, A and C). Similarly, the binding of Leu-SCC1-GST to <sup>f</sup>UBR1 was inhibited by Leu-Ala but neither by Arg-Ala (31), nor by Ala-Leu, nor by Leu + Ala (a mixture of free amino acids) (Fig. 4D).

In agreement with earlier findings (8), both full-length <sup>f</sup>UBR1 and UBR1<sup>1–1140f</sup> (N-terminal “half” of <sup>f</sup>UBR1) exhibited qualitatively indistinguishable patterns of binding specificity (Fig. 4, E and F), indicating that UBR1<sup>1–1140f</sup> contained the type-1 and type-2 binding sites. It should be noted that whereas Arg-OMe (in contrast to Arg-Ala) did not inhibit the binding of Arg-SCC1-GST to either UBR1<sup>1–1140f</sup> or full-length <sup>f</sup>UBR1, the analogous methyl ester Leu-OMe inhibited the binding of Leu-SCC1-GST apparently as efficaciously as did Leu-Ala (Fig. 4, C–F). Yet another difference between the inhibition patterns of type-1 and type-2 sites was a comparably strong inhibition, by either Leu-Ala or Leu-Asp, of the binding of Leu-SCC1-GST to UBR1 *versus* the absence of inhibition, by Arg-Asp (in contrast to Arg-Ala), of the binding of Arg-SCC1-GST to UBR1 (Fig. 4, C–F). Detailed understanding of these differences requires the knowledge of the crystal structure of UBR1.

The binding of UBR1 to destabilizing N-terminal residues of polypeptides was also examined using the X-peptide assay, which employed a set of otherwise identical 12-mer peptides (termed X-nsP4pep) whose sequence X-Ile-Phe-Ser-Thr-Asp-Thr-Gly-Pro-Gly-Gly-Cys (X = Arg or Phe) was derived, in part, from the N-terminal sequence of nsP4, the RNA polymerase of the Sindbis virus and a physiological N-end rule substrate (27, 62). Purified X-nsP4pep peptides were cross-linked to microbeads through their C-terminal Cys residue (8, 31, 32). Both full-length <sup>f</sup>UBR1 and several of its truncated derivatives were overexpressed in *S. cerevisiae* and assayed for their binding to either Arg-nsP4pep or Phe-X-nsP4pep. Whereas <sup>f</sup>UBR1<sup>1–717</sup>, the 717-residue N-terminal fragment of the 1,950-residue UBR1, was capable of specific binding to X-nsP4pep peptides, shorter N-terminal fragments of UBR1 did not bind (Fig. 4, G and H). In addition, UBR1<sup>209–1140f</sup>, which differed from the binding-competent UBR1<sup>1–1140f</sup> by deletion of the first 208 residues, did not bind to either Arg-nsP4pep or Phe-X-nsP4pep (Fig. 4, G, H and J). All of these findings were consistent with the conclusions from genetic mapping of the type-1 and type-2 sites (Fig. 1C).

**Measurements of Affinity between UBR1 and Peptide Reporters Using Fluorescence Polarization Assay**—To measure the binding of UBR1 to different N-terminal residues of otherwise identical polypeptides, we employed both fluorescence polarization (FP) (63, 64, 66) and surface plasmon resonance (SPR) (72, 73). These measurements used purified UBR1<sup>1–1140f</sup> (Fig. 4I). Its specific binding to N-terminal residues of either protein-size substrates or short peptides was indistinguishable from that of full-length <sup>f</sup>UBR1 in GST pulldown assays (Fig. 4, A–F).

The otherwise identical Arg-nsP4pep, Phe-nsP4pep, and Gly-nsP4pep peptides, with type-1 destabilizing, type-2 destabilizing, and stabilizing N-terminal residues, respectively (Fig. 1A), were C-terminally conjugated to Alexa Fluor-488, followed by purification of the resulting fluorescent peptides by HPLC and verification of their structures by mass spectrometry (see “Experimental Procedures”).

The concentration of X-nsP4pep (C-terminal symbol denotes fluorescent tag) in FP assays was set at 10 nM, well below the (anticipated) micromolar range of affinities between UBR1 and test peptides. As expected (8), both Arg-nsP4pep and Phe-nsP4pep interacted with UBR1<sup>1–1140f</sup>. The calculated  $K_d$  values (see “Experimental Procedures”) were  $\sim 1.0$  and  $\sim 0.7 \mu\text{M}$ , respectively. In contrast, no binding to UBR1<sup>1–1140f</sup> could be detected with the otherwise identical Gly-nsP4pep, *i.e.* the corresponding  $K_d$  was at least 0.1 mM or higher (Fig. 5, A and B). The affinities of X-nsP4pep peptides for UBR1<sup>1–1140f</sup> were also measured in a competition FP assay, in which, for example, the binding of Phe-nsP4pep to UBR1<sup>1–1140f</sup> was titrated by the addition of Alexa lacking (unlabeled) Phe-nsP4pep (Fig. 5F). The corresponding  $K_d$  was  $\sim 2 \mu\text{M}$ , close to the value deduced from direct binding FP assay (Fig. 5, B and F). In contrast, the competition by unlabeled Arg-nsP4pep (a type-1 destabilizing N-terminal residue) or by unlabeled Gly-nsP4pep (a stabilizing N-terminal residue) for the binding of Phe-nsP4pep to UBR1<sup>1–1140f</sup> was too weak to measure by FP (Fig. 5F). The  $K_d$  value of Arg-nsP4pep binding to UBR1<sup>1–1140f</sup> that was deduced from a similar competition assay, using unlabeled Arg-nsP4pep as a competitor, was  $\sim 1.2 \mu\text{M}$ , close to the value of  $\sim 1.0 \mu\text{M}$  from direct-binding assay (Fig. 5, A and C). Interestingly, however, the unlabeled Phe-nsP4pep could detectably compete with the binding of (labeled) Arg-nsP4pep to UBR1<sup>1–1140f</sup> (Fig. 5C), with the apparent  $K_d$  of  $\sim 11 \mu\text{M}$ , *i.e.* Phe-nsP4pep was an  $\sim 10$ -fold weaker inhibitor of the binding of Arg-nsP4pep to UBR1<sup>1–1140f</sup> than Arg-nsP4pep itself. As to unlabeled Gly-nsP4pep, its apparent binding to the type-1 site of UBR1<sup>1–1140f</sup> was weaker still but could still be detected in this competition assay, with the corresponding (apparent)  $K_d$  of  $\sim 36 \mu\text{M}$  (Fig. 5C).

We conclude that the type-1 and type-2 substrate-binding sites of UBR1 bind to the corresponding N-terminal residues of model substrates with approximately equal affinities ( $K_d$  of  $\sim 1 \mu\text{M}$ ). We also conclude that the UBR1 type-2 site, which binds to bulky hydrophobic N-terminal residues (Fig. 1A), is significantly more discriminating than the type-1 site. Specifically, we could not detect the binding of noncognate N-terminal residues to the type-2 site of UBR1, in either qualitative or quantitative assays (Fig. 4 and Fig. 5, B and F), whereas a type-2 N-terminal residue could weakly compete with a type-1 N-terminal residue for the binding to the type-1 site of UBR1, and a stabilizing N-terminal residue could also compete, albeit even more weakly than a type-2 residue (Fig. 5, A–F).

We also carried out competition assays with unlabeled dipeptides and other dipeptide size compounds *versus* either Arg-nsP4pep or Phe-nsP4pep (Fig. 5, D, E and G). Some of these competitors were also used in qualitative binding assays (Fig. 4, D and E). The results of FP-based competition assays indicated that dipeptides (as distinguished from 12-mer


## UBR1 Ubiquitin Ligase

X-nsP4pep peptides) with cognate N-terminal residues were significantly (5–10-fold) weaker competitors relative to unlabeled cognate X-nsP4pep peptides (Fig. 5, D and G), and that dipeptides (or analogous compounds) with noncognate N-terminal residues were either not competitors at all or much weaker competitors (see the legend to Fig. 5, D and G for details). Among the tested dipeptide sequences, Ala at position 2 of an otherwise cognate dipeptide (Arg-X or Leu-X) resulted in best competitor dipeptides, whereas a negatively charged (Asp) residue at position 2 significantly decreased the affinity of a dipeptide for the corresponding (type-1 or type-2) substrate-binding site of UBR1 (Fig. 5, D and G). A basic (Arg or Lys) residue at position 2 was not as detrimental for the interaction of dipeptide with UBR1 (Fig. 5, D and G).

Although the length of a competitor peptide is less important than whether or not it bears a cognate N-terminal residue, the data of Fig. 5, H and I, indicate that the length of a peptide (in the tested range) is a significant, apparently independent parameter that determines its affinity for UBR1. One possibility is that the C-terminal carboxyl group of the peptide (e.g. its negative charge) would weaken the binding of peptide to its cognate (type-1 or type-2) binding site of UBR1, unless the peptide is long enough to place its C-terminal carboxyl group away from the binding site. This interpretation would also account for the fact that free “cognate” amino acids (in contrast to dipeptides bearing them as N-terminal residues) do not bind to UBR1 (Fig. 4, C and E).

**Measurements of Affinity between UBR1 and Model Peptides Using Surface Plasmon Resonance**—To measure the affinity between UBR1<sup>1–1140f</sup> and 12-mer X-nsP4pep peptides using a technique other than FP (Fig. 5), we employed SPR and BIAcore-2000 (65, 66, 72, 73). Phe-nsP4pep, Arg-nsP4pep, or Gly-nsP4pep, modified to bear a C-terminal biotin moiety (see “Experimental Procedures”), were immobilized on streptavidin-coated sensor chips. Purified UBR1<sup>1–1140f</sup> (see Fig. 4I) was serially diluted in the running buffer and injected over the chip surface for 80 s. BIAcore readouts were corrected by subtracting readouts from the mock

surface (lacking an X-peptide) as well as readouts from buffer-only (control) injections. Raw data were processed using Scrubber (BioLogic Software) and were globally fit using CLAMP (65), yielding the corresponding  $K_d$  values. As shown in Fig. 6, BIAcore detected the binding of UBR1<sup>1–1140f</sup> to either Arg-nsP4pep (bearing a type-1 destabilizing N-terminal residue) or Phe-nsP4pep (bearing a type-2 destabilizing N-terminal residue), with the  $K_d$  values of  $\sim 1.2$  and  $\sim 1.0$   $\mu\text{M}$ , respectively (Fig. 6), in excellent agreement with the results of FP-based measurements (Fig. 5 and see preceding



section). In contrast, the otherwise identical Gly-nsP4pep, bearing a stabilizing N-terminal residue, did not exhibit a detectable binding to UBR1<sup>1-1140f</sup> (Fig. 6C). These BIAcore-based findings (Fig. 6) demonstrated yet again (in addition to GST pulldown and FP-based data) that at least the bulk of the *in vivo* specificity of UBR1 for N-end rule substrates (Fig. 1, A and B) (see Introduction) stems from differences in its physical affinity for destabilizing *versus* stabilizing N-terminal residues in the N-end rule.

**Nonspecific Binding of Purified UBR1 to CUP9, and Restoration of Specificity through Chaperones and Macromolecular Crowding**—Through its type-1 and type-2 sites, the 225-kDa UBR1 can bind to primary destabilizing N-terminal residues in proteins or short peptides apparently “nonconditionally,” *i.e.* under all conditions tested (8) (Figs. 4–6). In contrast, UBR1 can bind, through its third binding site, to its physiological substrate CUP9 only if the type-1 and type-2 sites of UBR1 are occupied by cognate N-terminal residues of ligands such as dipeptides (8) (*e.g.* Fig. 7, E–G, lanes 2 and 3). This dependence of the UBR1-CUP9 interaction (via the C terminus-proximal degreon of CUP9 (8) (Fig. 7, B and C)) on the state of occupancy of other two binding sites of UBR1 yields, *in vivo*, a positive feedback circuit through which *S. cerevisiae* can sense the presence of extracellular peptides and accelerate their uptake (8, 40) (see Introduction). The negligible binding of CUP9 by UBR1 in the absence of occupancy of its type-1/2 sites (*e.g.* Fig. 7, E–G, lanes 2 and 3) is thus the consequence of a negligible fraction of UBR1 molecules, under these conditions, that exhibit an “open” (active) CUP9-binding site.

The binding of type-1/2 ligands to the corresponding sites of UBR1 increases, in an ensemble of UBR1 molecules, the probability of a conformational transition that “opens up” the CUP9-binding site of UBR1 (8). The type-1/2 sites of UBR1 encompass its N-terminal and proximal UBR domain (Fig. 1C and Introduction). The allosteric influence of UBR1-bound dipeptides on the probability of transition that induces the UBR1-CUP9 interaction was shown to require the evolutionarily conserved C-terminal region of UBR1 that


includes two critical cysteines, Cys<sup>1703</sup>, and Cys<sup>1706</sup> (8). In particular, UBR1<sup>1-1140f</sup>, the N-terminal “half” of UBR1, retains all three of its substrate-binding sites but exhibits a constitutively open (active) CUP9-binding site. More recent findings, using UBR1 derivatives that contained sequences allowing site-specific cleavages of UBR1, indicated that a conformational transition in UBR1 that “opens up” its CUP9-binding site is “subtle” in that it does not appear to involve a large scale repositioning of UBR1 domains.<sup>4</sup>

GST pulldowns with UBR1 *versus* GST-CUP9 were carried out in the presence of yeast extract (8) (*e.g.* Fig. 7, E–G, lanes 2 and 3). We repeated these assays with purified UBR1 (see “Experimental Procedures”) and GST-CUP9. Surprisingly, the specificity of UBR1-CUP9 interaction, *i.e.* its dependence on the presence of dipeptides with destabilizing N-terminal residues, as well as its dependence on the presence of C-terminal degreon of CUP9 (67) were abolished with purified UBR1; it bound to GST-CUP9 irrespective of the presence or absence of dipeptides and irrespective of the presence or absence of the UBR1-specific degreon of CUP9 (Fig. 7, C and F, and data not shown). These effects of using purified UBR1 (as distinguished from UBR1 in the presence of yeast extract) were also observed with its N-terminal fragment UBR1<sup>1-1140f</sup> (Figs. 4K and 7B). For example, in the presence of yeast extract, UBR1<sup>1-1140f</sup> bound to CUP9 constitutively (*i.e.* independently of the presence of dipeptides) (8) but *specifically* (*i.e.* depending on the presence of the CUP9 degreon) (Fig. 7B). However, purified UBR1<sup>1-1140f</sup> bound either to full-length CUP9 (containing its C-terminal degreon) or to C-terminally truncated CUP9<sup>1-221</sup> that lacked the degreon (Fig. 4K, lanes 1–6). The same pattern was observed with purified full-length UBR1 *versus* CUP9<sup>L294P</sup> that contained a previously characterized degreon-inactivating missense mutation (8) (Fig. 7I).

We found that the *specificity* of these interactions, *i.e.* their dependence on the presence of the CUP9 degreon, could be

<sup>4</sup> Z. Xia and A. Varshavsky, unpublished data.

**FIGURE 4. Specific interactions between UBR1 and its physiological substrates or model ligands.** A, GST pulldown assays with full-length, FLAG-tagged UBR1 and immobilized Arg-SCC1-GST. Equal amounts of extract from *S. cerevisiae* that expressed UBR1 were incubated with glutathione-Sepharose beads preloaded with Arg-SCC1-GST, in the presence of indicated concentrations of either the Arg-Ala (RA) or Ala-Arg (AR) dipeptides. The beads-associated UBR1 was eluted from the beads, fractionated by SDS-PAGE, and detected by immunoblotting with anti-FLAG antibody (see “Experimental Procedures”). B, same as in A but with Leu-SCC1-GST and either Leu-Ala (LA) or Ala-Leu (AL). C, same assay format, with Arg-SCC1-GST. Lane 1, 5% refers to a directly loaded sample of UBR1-containing yeast extract that corresponded to 5% of the amount of extract in GST pulldowns of this panel. Lane 2, Arg-SCC1-GST pulldown assay with UBR1 in the presence of 1 mM AR dipeptide (single-letter notations for amino acids). Lanes 3–10, same as lane 2 but with either A+R (1 mM free Ala and 1 mM free Arg), or RA, or R-OMe (O-methyl ester), or agmatine (see the main text), or RD, or RK, or RF, or RL, all of them at 1 mM. D, same as in C but with Leu-SCC1-GST and different dipeptides or related compounds, as shown. Lane 1, Met-SCC1-GST (instead of Leu-SCC1-GST); note the absence of its interaction with UBR1, in contrast to Leu-SCC1-GST and Arg-SCC1-GST. E, same as in C, but with UBR1<sup>1-1140f</sup>, the N-terminal half of UBR1. F, same as in D but with UBR1<sup>1-1140f</sup>. G, input samples of UBR1<sup>1-1140f</sup> and its derivatives. Lane 1, UBR1<sup>1-1140f</sup>. Lanes 2–7, UBR1<sup>1-717</sup>, UBR1<sup>209-1140f</sup>, UBR1<sup>454-1140f</sup>, UBR1<sup>710-1140f</sup>, UBR1<sup>866-1140f</sup>, and UBR1<sup>ha</sup>, respectively. These derivatives of UBR1 were overexpressed in *S. cerevisiae* as described for UBR1<sup>1-1140f</sup>. The asterisk denotes a protein cross-reacting with anti-FLAG antibody. UBR1<sup>ha</sup> (lane 7) was employed as a (negative) control for antibody specificity. 10% input refers to a directly loaded sample of yeast extract that corresponded to 10% of the amount of extract in GST pulldowns of H and J. H, X-peptide assay (see “Experimental Procedures”) with UBR1<sup>1-1140f</sup> and its derivatives, described in G. UBR1<sup>1-1140f</sup> and UBR1<sup>1-717</sup>, but not the other UBR1 derivatives of G bound to immobilized Arg-nsP4pep peptide. I, lane 1, molecular mass markers. Lane 2, Coomassie-stained SDS-PAGE pattern of (overexpressed) UBR1<sup>1-1140f</sup> that was purified from yeast extract using anti-FLAG affinity chromatography and used for GST-CUP9 pulldowns (see K and “Experimental Procedures”). J, same as in H but with immobilized Phe-nsP4pep peptide. K, lane 1, 2% input. Lane 2, GST-CUP9 pulldown with UBR1<sup>1-1140f</sup> in *S. cerevisiae* extract. Lane 3, same as lane 2, but with GST-CUP9<sup>1-221</sup>, a C-terminally truncated mutant of the 306-residue CUP9 that lacks its C-terminal degreon (67). Note the absence of binding of UBR1<sup>1-1140f</sup> (in yeast extract) to GST-CUP9<sup>1-221</sup>, in contrast to its binding to full-length GST-CUP9<sup>1-306</sup>. Lane 4, 10% input. Lane 5, same as lane 2 but with purified UBR1<sup>1-1140f</sup>, as distinguished from UBR1<sup>1-1140f</sup> in yeast extract. Lane 6, same as lane 5 but with GST-CUP9<sup>1-221</sup>. Note that purified UBR1<sup>1-1140f</sup>, in contrast to the same protein in yeast extract, binds to both degreon-containing (lane 5) and degreon-lacking CUP9 (lane 6). Lane 7, same as lane 5 but with ovalbumin (at 50 mg/ml) added to UBR1<sup>1-1140f</sup> before GST pulldown with full-length GST-CUP9. Lane 8, same as lane 7 but with GST-CUP9<sup>1-221</sup>. Note restoration of the binding specificity of UBR1<sup>1-1140f</sup> in the presence of ovalbumin. Lanes 9 and 10, same as lanes 5 and 6 but “empty” yeast extract was added to purified UBR1<sup>1-1140f</sup> before GST pulldowns with either full-length GST-CUP9 (lane 9) or degreon-lacking GST-CUP9<sup>1-221</sup>.




**FIGURE 5. Measurements of affinity between UBR1<sup>1-1140f</sup> and peptides with different N-terminal residues using FP assay.** *A*, purified UBR1<sup>1-1140f</sup> (Fig. 4f) was incubated, at increasing concentrations, with either Arg-nsP4pep (curve 1) or Gly-nsP4pep (curve 2), each of them at 10 nM (C-terminal diamond in the text and a star in the figure denote a C-terminal fluorescent tag; see “Experimental Procedures”). Note the binding to Arg-nsP4pep (bearing a type-1 destabilizing N-terminal residue) and the absence of significant binding to Gly-nsP4pep (bearing a stabilizing N-terminal residue). *B*, same as in *A* but with Phe-nsP4pep versus Gly-nsP4pep (curves 1 and 2, respectively). *C*, competition assay, with UBR1<sup>1-1140f</sup> at 1 μM, Arg-nsP4pep at 10 nM, versus increasing concentrations of unlabeled Arg-nsP4pep, Phe-nsP4pep, or Gly-nsP4pep (curves 1–3, respectively). *D*, same as in *C* but with unlabeled dipeptides as competitors, at indicated concentrations. Curves 1–6, LA, AR, FA, RD, RK, and RA, respectively (single-letter abbreviations for amino acids). *E*, same as in *D*, but with an equimolar mixture of Arg and Ala (curve 1), Arg-OMe (R-OMe) (curve 2), and Arg-Ala (RA) as unlabeled competitors. *F*, same as in *C*, but with fluorescent Phe-nsP4pep, with UBR1<sup>1-1140f</sup> at 0.7 μM, and the competition with unlabeled Gly-nsP4pep, Arg-nsP4pep, or Phe-nsP4pep (curves 1–3, respectively). *G*, same as in *D* but with Phe-nsP4pep as a labeled peptide, with UBR1<sup>1-1140f</sup> at 0.7 μM, and with unlabeled dipeptides (or their derivatives) as competitors. Curves 1–7, LD, L-OMe (Leu-OMe), LG, LL, LR, LA, and WA, respectively. *H*, same as in *G*, but with Arg-nsP4pep as a labeled peptide, with UBR1<sup>1-1140f</sup> at 0.7 μM, and with unlabeled competitors GGGG, RGD, RGDS, RG, or RAGESGSGC (single-letter abbreviations for amino acids) (curves 1–5, respectively). The RAGES sequence of the latter peptide is identical to the N-terminal sequence of the separate-produced C-terminal fragment of SCC1, a physiological N-end rule substrate (see “Results” and “Discussion”). *I*, same as in *H*, but with Phe-nsP4pep as a labeled peptide, with UBR1<sup>1-1140f</sup> at 0.7 μM, and with unlabeled GGGG, FG, FGG, FGGF, FA, and Phe-nsP4pep peptide as competitors (curves 1–6, respectively).

restored if GST-CUP9 pull-downs with purified UBR1<sup>1-1140f</sup> or purified UBR1 were carried out in the presence of a “carrier” protein such as ovalbumin, at concentrations (10–50 mg/ml) that would be expected to produce “macromolecular crowding” (Fig. 4K, lanes 4–6, compare with lanes 7 and 8; Fig. 7F, lanes 5 and 6, compare with lanes 7 and 8; Fig. 7G, lanes 9 and 10, compare with lanes 5 and 6; Fig. 7K, lanes 5 and 6, compare with lanes 7 and 8). These terms refer to volume-exclusion and related effects that recapitulate, in part, the properties of intracellular milieu, where the total protein concentration can be as high as 200–400 mg/ml (74–76).

As expected, and similarly to the effect of ovalbumin, the re-addition of <sup>f</sup>UBR1-lacking yeast extract to purified <sup>f</sup>UBR1 also restored the specificity of UBR1 binding to GST-CUP9 (Fig. 7E). We noticed that GST-CUP9 interacted not only with

<sup>f</sup>UBR1 in the yeast extract but also with another protein that was present in extracts irrespective of the presence of <sup>f</sup>UBR1 (data not shown). Mass spectrometry of that protein identified it as EF1A, which functions as a translation elongation factor, a protein chaperone, and is a highly abundant protein (Ref. 77 and references therein). We employed two chromatographic steps, DEAE-Sepharose and CM-Sepharose chromatography, to purify *S. cerevisiae* EF1A to near homogeneity (Fig. 7H). The addition of purified EF1A to GST-CUP9 pull-downs with purified <sup>f</sup>UBR1, at the EF1A concentration of 1.2 mg/ml (a relatively low level, in comparison to minimally effective concentrations of ovalbumin), was found to restore the specificity of UBR1-CUP9 interactions. Specifically, in the presence of purified EF1A, a significant binding of purified <sup>f</sup>UBR1 to GST-CUP9 was observed only in the presence of dipeptides with destabi-



**FIGURE 6. Measurements of affinity between UBR1<sup>1-1140f</sup> and peptides with different N-terminal residues using surface plasmon resonance.** A, BIAcore sensograms (see “Experimental Procedures”) illustrating the binding of UBR1<sup>1-1140f</sup> to the immobilized 12-residue Arg-nsP4pep peptide, bearing a type-1 primary destabilizing N-terminal residue. RU, resonance units. Curves 1–5 correspond to the passing of purified UBR1<sup>1-1140f</sup>, at either 0.188, 0.375, 0.75, 1.5, or 3  $\mu\text{M}$ , over immobilized Arg-nsP4pep. B, same as in A but with immobilized Phe-nsP4pep, bearing a type-2 primary destabilizing N-terminal residue (Fig. 1A). C, same as in A but with Gly-nsP4pep bearing a stabilizing N-terminal residue (no detectable binding to UBR1<sup>1-1140f</sup> at any of its tested concentrations). D and E, binding isotherms (derived from the data in A and B, respectively) for Arg-nsP4pep and Phe-nsP4pep (see “Experimental Procedures”).

lizing N-terminal residues (Fig. 7G, lanes 7 and 8, compare with lanes 2–6 and 9 and 10).

A parsimonious interpretation of these findings with purified UBR1 *versus* its supplementation with ovalbumin, or with yeast extract, or with EF1A is that CUP9, a transcriptional repressor, functions *in vivo* as a complex containing “global” corepressors TUP1 and SSN6 (78). In the absence of these CUP9 ligands, the CUP9 moiety in purified GST-CUP9 may exhibit a “sticky” region(s) that mediates a nonspecific interaction between CUP9 and UBR1. This region(s) of CUP9 may be shielded from UBR1 by interactions with either EF1A, acting as a chaperone, and/or with another chaperone-like proteins in the yeast extract, thus allowing a specific UBR1-CUP9 interaction to be detected. Because “crowding” levels of ovalbumin (10–50 mg/ml) also restore the specificity of UBR1-CUP9 interaction (Fig. 4K and Fig. 7, F and G), the presumed sticky region(s) of CUP9 may be partially unfolded in the absence of EF1A or ovalbumin. *In vivo*, CUP9 is likely to be targeted by UBR1 for ubiquitylation (and subsequent degradation) as a part of the TUP1-SSN6-CUP9 complex (79, 80). The previously discovered subunit selectivity of the N-end rule pathway (20, 23) is expected to make possible selective degradation of the CUP9 moiety in the TUP1-SSN6-CUP9 complex *in vivo*, leaving the corepressor TUP1-SSN6 intact. This model remains to be addressed experimentally.

**Synergistic Effects of Type-1/2 Dipeptides in a UBR1-dependent Ubiquitylation System**—Our studies of the targeting of CUP9 by the UBR1 Ub ligase (8, 40) included the development of an *in vitro* system that consisted exclusively of small compounds and purified recombinant proteins (Ub, UBA1, RAD6, UBR1, and CUP9) (see “Experimental Procedures” and Ref. 67). This system exhibited the UBR1-dependent, RAD6-dependent polyubiquitylation of CUP9 that was enhanced by single dipeptides such as Trp-Ala or Lys-Ala that bore destabilizing N-terminal residues but was not enhanced by compositionally identical single dipeptides such as Ala-Trp or Ala-Lys, which bore a stabilizing N-terminal residue (40, 67). As with most such systems, the extent of its specificity, in this case the extent of its UBR1 dependence vis-à-vis polyubiquitylation of CUP9, was a function of both UBR1, RAD6, and Ub concentrations (Ref. 67 and data not shown).

In this present study, we asked whether the specificity of the system could also recapitulate, at the level of UBR1-dependent polyubiquitylation

of CUP9, the previously demonstrated dependence of the UBR1-CUP9 *in vitro* interaction (assayed by GST pull-downs) on the presence of *both* type-1 and type-2 dipeptides (e.g. both Arg-Ala and Leu-Ala) (8) (see also Fig. 7). Indeed, we observed a clear enhancement of the UBR1-dependent CUP9 polyubiquitylation upon the addition of both Arg-Ala and Leu-Ala (at micromolar levels), as distinguished from either Arg-Ala alone or Leu-Ala alone (Fig. 8). Specifically, little polyubiquitylated CUP9 was formed in reactions that contained no added dipeptides (Fig. 8, lane 2). Some polyubiquitylated CUP9, bearing relatively short poly-Ub chains, was formed in the presence of a mixture of Leu-Ala (a type-2 dipeptide) and Ala-Arg (bearing a stabilizing N-terminal residue), at 2  $\mu\text{M}$  each (Fig. 8, lane 5). The distribution of poly-Ub chain sizes shifted slightly upward at 10  $\mu\text{M}$  of Leu-Ala plus Ala-Arg (Fig. 8, lane 6; compare with lanes 2 and 5). However, when a mixture of type-1 (Arg-Ala) and type-2 (Leu-Ala) dipeptides was present, the polyubiquitylation of CUP9 was detectable already at 0.8  $\mu\text{M}$  of each dipeptide (Fig. 8, lane 7; compare with lane 2). The average size of CUP9-linked poly-Ub chains greatly increased at 2  $\mu\text{M}$  of type-1/2 dipeptides, and the average size of such chains was much higher than the one observed at the same concentration of Leu-Ala plus Ala-Arg (Fig. 8, lane 8; compare with lane 5). Finally, at 5  $\mu\text{M}$  of type-1/2 dipeptides, the size of most poly-Ub chains became too large for the resulting CUP9 conjugates to be frac-


## UBR1 Ubiquitin Ligase

tionated under conditions used, resulting in a diffuse "band" of large conjugates near the origin of the gel (Fig. 8, lane 9; compare lanes 7 and 8, and also with lane 6, which illustrates the average size of poly-Ub chains in the presence a type-2 dipeptide (Leu-Ala plus Ala-Arg) at 10  $\mu$ M, twice as high as the 5  $\mu$ M level of type-1/2 dipeptides together). Thus, in addition to the previously demonstrated dependence of the physical binding of UBR1 to CUP9 on the presence of both type-1 and type-2 dipeptides (8) (see also Fig. 7), our present findings (Fig. 8) strongly suggest that the processivity of polyubiquitylation of CUP9 by the UBR1-RAD6 Ub ligase is increased when both of the type-1 and type-2 binding sites of UBR1 are occupied by cognate dipeptides. One constraint on possible mechanisms of UBR1 processivity stems from the fact that the bulk of either purified UBR1 or UBR1 in yeast extracts is a monomer, as determined by gel filtration (see Refs. 67, 70 and data not shown).

## DISCUSSION


Since the 1990 cloning of *S. cerevisiae* UBR1, the first molecularly characterized E3 Ub ligase (70), it was clear that at least the bulk of enzymatic (polyubiquitylation) specificity of the UBR1-RAD6 holoenzyme toward polypeptides with primary destabilizing N-terminal residues (Fig. 1A) stems from selective binding of UBR1 to those residues, rather than from the effects of a bound N-terminal residue of a substrate on the kinetics of substrate ubiquitylation by UBR1-RAD6. For example, immunoprecipitation of an epitope-tagged UBR1 from yeast extracts containing Arg- $\beta$ gal (an N-end rule substrate) versus the otherwise identical Val- $\beta$ gal (not an N-end rule substrate) coprecipitated Arg- $\beta$ gal but not Val- $\beta$ gal (70). Quantitative measurements, in this study, of these differential affinities of UBR1 confirmed and extended the earlier inferences. Specifically, using both FP and SPR, we found that UBR1 bound to either type-1 (basic) or type-2 (bulky hydrophobic) N-terminal residues of 12-mer X-peptides with a  $K_d$  of  $\sim 1 \mu$ M. In contrast, neither FP nor SPR could detect the binding of UBR1 to an otherwise identical reporter peptide bearing a stabilizing N-terminal residue such as Gly (Figs. 5 and 6).

The above affinity of the 225-kDa yeast UBR1 N-recognin for cognate (primary destabilizing) N-terminal residues (Fig. 1A) is in agreement with the approximately equal affinity of ClpS, the 12-kDa *E. coli* N-recognin (see Introduction), for its cognate



(bulky hydrophobic) N-terminal residues (2, 13). The relatively high rate of UBR1 dissociation from substrate proteins (implied by the equilibrium  $K_d$  of  $\sim 1 \mu$ M for UBR1 binding to N-degrons) may facilitate the transfer of a targeted, polyubiquitylated substrate to downstream components of the N-end rule pathway, such as Ub-binding chaperones and the 26 S proteasome. Although UBR1 is a scarce protein in *S. cerevisiae* ( $\sim 300$  molecules per haploid cell<sup>5</sup>), the UBR1-dependent N-end rule pathway is highly efficacious. For example, wild-type levels of UBR1 sufficed to reduce the steady-state level of a reporter N-end rule substrate such as Arg- $\beta$ gal to less than 5% of its level in the absence of UBR1, even under conditions where Arg- $\beta$ gal was expressed from the induced P<sub>GAL1</sub> promoter on a high copy plasmid and would have been an abundant protein in the absence of its degradation by the N-end rule pathway (9, 54, 69). UBR1 was also found to interact with specific subunits of the 26 S proteasome (81), in apparent contradiction to the notion of rapid transfer of a UBR1-targeted substrate to downstream effectors. One possibility is that a significant fraction of UBR1

<sup>5</sup> C.-S. Hwang and A. Varshavsky, unpublished data.



**FIGURE 8. Synergistic effects of type-1/2 dipeptides in a UBR1-dependent ubiquitylation system.** Reactions consisting of purified *S. cerevisiae* Ub, purified UBA1 (E1, Ub-activating enzyme), RAD6 (the N-end rule pathway E2, Ub-conjugating enzyme), UBR1 (the N-end rule pathway E3 Ub ligase), <sup>35</sup>S-labeled, purified CUP9, and ATP were supplemented with pairs of purified dipeptides, at indicated concentrations. The pairs of added dipeptides were Arg-Ala plus Ala-Leu (RA+AL), or Leu-Ala plus Ala-Arg (LA+AR), or Arg-Ala plus Leu-Ala (RA+LA), or Ala-Arg plus Ala-Leu (AR+AL). The reactions were incubated at 30 °C for 10 min, followed by SDS-10% PAGE and autoradiography (see "Experimental Procedures"). Unmodified CUP9 and CUP9-linked poly-Ub chains are indicated on the left. Asterisk on the right denotes a protein present in the initial CUP9 sample, possibly an SDS-resistant dimer of CUP9. Lane 1, purified CUP9 (input). Lanes 2–10, same as in B, but a set of independently performed reactions, with different concentrations of added dipeptide pairs. Note a synergistic enhancement of CUP9 polyubiquitylation in the presence of RA+LA (lane 9).

molecules might be associated, at any given time, with the (much more abundant) 26 S proteasome. In other words, the UBR1-dependent targeting of N-end rule substrates may take

place in the context of a UBR1-proteasome complex. This model remains to be addressed experimentally.

Genetic screens, in this study, for *UBR1* mutants that lost the ability to target type-1 N-end rule substrates but retained the targeting of type-2 substrates and vice versa have yielded both classes of mutants, thereby indicating a modular organization of the type-1 and type-2 substrate-binding sites of UBR1. The type-1 site (it binds to N-terminal Arg, Lys, or His) is located primarily in the ~70-residue UBR domain of UBR1, whereas the type-2 site (it binds to N-terminal Trp, Phe, Tyr, Leu, or Ile) resides at least in part downstream of the type-1 site and, moreover, may partially overlap (or functionally interact) with the third substrate-binding site of UBR1, the one that targets CUP9 (Figs. 1C and 3). We also found that the previously characterized UBR1-dependent *in vitro* ubiquitylation system (40, 67) exhibited a synergistic effect of two dipeptides with cognate type-1 and type-2 N-terminal residues on the rate of CUP9 polyubiquitylation (Fig. 8). This ubiquitylation-based result extended our earlier observation (8) (see also Fig. 7) that the physical binding of UBR1 to CUP9 *in vitro* required the occupancy of both type-1 and type-2 binding sites of UBR1 by added dipeptides.

Another finding of this study is that a specific (CUP9 degradespecific) *in vitro* interaction between GST-CUP9 and UBR1 required the presence of either yeast extract, or the translation factor EF1A (which is known to function as a chaperone), or ovalbumin, the latter at concentrations that produce macromolecular crowding (Figs. 4 and 7). As described under "Results,"

**FIGURE 7. CUP9 mutants, UBR1-CUP9 interactions, and effects of macromolecular crowding on the specificity of interaction between purified proteins.** A, map of the 306-residue CUP9 and its truncation mutants. B, GST pull-down assays with UBR1<sup>1-1140F</sup> and GST fusions to indicated CUP9 derivatives (see also the legend to Fig. 4, "Experimental Procedures" and the main text). Lane 1, 5% refers to a directly loaded sample of UBR1<sup>1-1140F</sup>-containing yeast extract that corresponded to 5% of the amount of extract in GST pull-downs of this panel. Lane 2, GST pull-down with UBR1<sup>1-1140F</sup> and GST fusion to wild-type CUP9. Lanes 3–7, same as lane 2 but with GST fusions to CUP9 mutants. Lane 8, same as lane 2, but GST lacking the CUP9 moiety. The band of UBR1<sup>1-1140F</sup> (retained on glutathione-Sepharose beads) is indicated. C, lane 1, same as lane 1 in B, except that the test *S. cerevisiae* extract contained full-length <sup>125</sup>I-UBR1. Lanes 2–9, GST pull-downs with <sup>125</sup>I-UBR1 and the indicated GST-CUP9 fusions. As indicated above the lanes, all samples except those in lanes 3 and 5 contained a mixture of Arg-Ala (RA) and Leu-Ala (LA) dipeptides, each of them at 1 mM (see "Experimental Procedures"). Lane 10, same as lane 2, but with GST alone. D, lane 1, molecular mass markers; single and double asterisks denote, respectively, 220 and 60 kDa. Lane 2, Coomassie-stained gel of purified full-length <sup>125</sup>I-UBR1. E, lane 1, same as lane 1 in C, but 2% of total <sup>125</sup>I-UBR1 in the assay. Lanes 2 and 3, same as lanes 3 and 2 (respectively) in C, but an independent experiment. Lane 4, same as lane 1 but with purified <sup>125</sup>I-UBR1. Lanes 5 and 6, same as lanes 2 and 3 but with purified <sup>125</sup>I-UBR1 to which was added an empty (lacking <sup>125</sup>I-UBR1) *S. cerevisiae* extract. Note that purified <sup>125</sup>I-UBR1 assayed in the presence of "added-back" yeast extract exhibited specific (dipeptides-dependent) binding to GST-CUP9 (lanes 5 and 6), indistinguishably from <sup>125</sup>I-UBR1 that had not been initially purified (lanes 2 and 3). F, lanes 1–4, same as lanes 1–4 in E but an independent experiment. Lane 4, same as lane 1, but 10% of the input sample of the purified <sup>125</sup>I-UBR1 (see lane 2 in D). Lanes 5 and 6, same as lanes 2 and 3 but with purified <sup>125</sup>I-UBR1. Note the lack of dependence of UBR1-CUP9 interaction on the presence of cognate dipeptides. Lanes 7 and 8, same as lanes 5 and 6 but GST pull-downs were carried out in the presence of added ovalbumin, at 10 mg/ml. Lanes 9 and 10, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 11 and 12, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 13 and 14, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 15 and 16, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 17 and 18, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 19 and 20, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 21 and 22, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 23 and 24, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 25 and 26, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 27 and 28, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 29 and 30, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 31 and 32, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 33 and 34, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 35 and 36, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 37 and 38, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 39 and 40, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 41 and 42, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 43 and 44, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 45 and 46, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 47 and 48, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 49 and 50, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 51 and 52, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 53 and 54, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 55 and 56, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 57 and 58, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 59 and 60, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 61 and 62, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 63 and 64, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 65 and 66, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 67 and 68, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 69 and 70, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 71 and 72, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 73 and 74, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 75 and 76, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 77 and 78, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 79 and 80, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 81 and 82, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 83 and 84, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 85 and 86, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 87 and 88, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 89 and 90, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 91 and 92, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 93 and 94, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 95 and 96, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 97 and 98, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. Lanes 99 and 100, same as lanes 7 and 8, but with purified EF1A added to the assay (to 1.2 mg/ml), instead of ovalbumin. I, lane 1, same as lane 1 in F, but an independent experiment. Lanes 2 and 3, same as lanes 2 and 3 in E or F, but with GST-CUP9<sup>L294P</sup>, a previously characterized missense mutant of CUP9 (in the region of its degron) that did not bind to UBR1 and was metabolically stabilized *in vivo* (8). Note the absence of binding of <sup>125</sup>I-UBR1 (in the extract) to GST-CUP9<sup>L294P</sup>, irrespective the absence or presence of dipeptides. Lane 4, same as lane 4 in F, but an independent experiment. Lanes 5 and 6, same as lanes 2 and 3 but with purified <sup>125</sup>I-UBR1. Note that purified <sup>125</sup>I-UBR1 binds to degenon-impaired GST-CUP9<sup>L294P</sup> and does so irrespective of the presence or absence of dipeptides. J, lane 1, same as lanes 4 in F or I, but an independent experiment. Lanes 2 and 3, same as lanes 5 and 6 in F, but in the presence of ovalbumin (at 50 mg/ml). Lanes 4 and 5, same as lanes 2 and 3 but with GST-CUP9<sup>L294P</sup>, instead of "wild-type" GST-CUP9. K, lane 1, same as lane 1 in F, but an independent experiment. Lanes 2 and 3, same as lanes 2 and 3 in F and G, but with GST-CUP9<sup>222-306</sup>, an N-terminally truncated CUP9. Note the retention of specific (dipeptides-modulated) binding of this CUP9 derivative to <sup>125</sup>I-UBR1. Lane 4, same as lane 4 in F, but an independent experiment. Lanes 5 and 6, same as lanes 2 and 3 but with purified <sup>125</sup>I-UBR1. Lanes 7 and 8, same as lanes 5 and 6, but with added ovalbumin (ov), at 50 mg/ml. Note the restoration of specific binding. L, an alternative UBR1-CUP9 binding assay in which the interactions were probed using coimmunoprecipitation of <sup>125</sup>I-UBR1 and <sup>35</sup>S-CUP9his<sub>6</sub>, a GST-lacking, full-length CUP9 bearing the N-terminal py epitope tag (see "Experimental Procedures"). FLAG-tagged <sup>125</sup>I-UBR1 in the yeast extract was incubated with beads-immobilized anti-FLAG antibody, followed by isolation of <sup>125</sup>I-UBR1-bearing beads by centrifugation, washes with binding buffer, and incubation with either purified <sup>35</sup>S-CUP9his<sub>6</sub> alone (lanes 2 and 3, upper panel) or in the presence of (added) UBR1-lacking yeast extract (lanes 4–7). The incubations were carried out in either the absence (lanes 2, 4, and 6) or the presence of Arg-Ala (RA) and Leu-Ala (LA) dipeptides, each of them at 1 mM. The beads containing immobilized <sup>125</sup>I-UBR1 were pelleted by centrifugation and washed, and the relative amounts of retained <sup>35</sup>S-CUP9his<sub>6</sub> were then determined by SDS-PAGE and immunoblotting with anti-py antibody (see "Experimental Procedures"). The upper panel shows the amounts of <sup>35</sup>S-CUP9his<sub>6</sub> that were bound to <sup>125</sup>I-UBR1 in the absence of added yeast extract (lanes 2 and 3) or in the presence of extract. Lane 1 shows the amount of <sup>35</sup>S-CUP9his<sub>6</sub> that corresponds to 10% of its input in each of the binding assays. The lower panel is the result of SDS-PAGE and immunoblotting (with anti-FLAG antibody) of <sup>125</sup>I-UBR1 that was eluted from anti-FLAG beads by the FLAG peptide, to verify the approximate equality of "input" levels of <sup>125</sup>I-UBR1 in each assay. Note that in the absence of added (UBR1-lacking) yeast extract, the interaction between <sup>125</sup>I-UBR1 and <sup>35</sup>S-CUP9his<sub>6</sub> was nonspecific, in that it was independent of the absence or presence of cognate dipeptides (lanes 2 and 3; compare with lanes 4–7). Lanes 6 and 7, same as lanes 4 and 5, but the input <sup>35</sup>S-CUP9his<sub>6</sub> was 2-fold higher.

## UBR1 Ubiquitin Ligase

this requirement is likely to stem from the fact that CUP9 functions in a complex with the general repressor TUP1-SSN6 (78–80). Thus, in contrast to the *in vitro* setting of purified GST-CUP9 (Fig. 7), UBR1 may not have access, *in vivo*, to (potentially) UBR1-interacting surfaces of CUP9 outside of its C-terminal proximal degron (8) (Fig. 7). It remains to be determined whether the short *in vivo* half-life of CUP9 (~5 min in the absence of UBR1-activating dipeptides in growth medium and <2 min in their presence (40)) reflects the UBR1-mediated targeting of CUP9 directly at chromatin, *i.e.* at transcriptional promoters that comprise the CUP9 regulon.

In the *S. cerevisiae* UBR1 E3, in its mammalian sequelogs UBR1/UBR2, and in some other N-recognins of mammals and plants (31, 32, 35) the UBR domain contains at least the type-1 substrate-binding site. A UBR domain is also present in UBR1 sequelogs that do not function as N-recognins. One example is the *S. cerevisiae* UBR2 E3, which is distinct from metazoan UBR2. Physiological substrates of *S. cerevisiae* UBR2 include RPN4, a short lived transcription factor that regulates the synthesis of proteasomal subunits (82, 83). The mammalian UBR3 E3 (its functions include regulation of olfaction) is yet another UBR domain-containing E3 Ub ligase that is not an N-recognin (29). Physiological ligands of the UBR domains in Ub ligases that are not N-recognins remain to be discovered.

Although prokaryotes lack the Ub system, they still contain the N-end rule pathway, albeit Ub-independent versions of it (10–15). The N-end rules of prokaryotes are subsets of the yeast N-end rule (which in turn is a subset of the mammalian N-end rule (Fig. 1A)). Despite these similarities between the rule books of eukaryotic and prokaryotic N-end rules, the underlying *mechanisms* in eukaryotes are quite distinct from those in prokaryotes, with differences beyond the absence of Ub in the latter. For example, the largest known prokaryotic N-end rule, the one of *Vibrio vulnificus*, a Gram-negative bacterium and human pathogen, is similar to the mammalian N-end rule; among 13 destabilizing N-terminal residues in the mammalian N-end rule (Fig. 1A), only Asn, Gln, and His are stabilizing residues in *V. vulnificus* (12). (N-terminal Asn and Gln are destabilizing in eukaryotes because of N-terminal amidases (Fig. 1A), which are absent from examined prokaryotes.) This rule book similarity between the mammalian and *V. vulnificus* N-end rules is a “convergent” one, in that it stems from different mechanisms. In particular, the N-terminal Arg and Lys residues are destabilizing in eukaryotic N-end rules because these residues are recognized directly (together with N-terminal His) by the type-1 substrate-binding sites of the Ub ligases of the pathway (see Introduction). By contrast, N-terminal Arg and Lys are *secondary* destabilizing residues in both *E. coli* and *V. vulnificus*, because of the presence of L/F<sup>K,R</sup>-transferase, an enzyme that is absent from examined eukaryotes and conjugates Leu (or Phe) to N-terminal Arg or Lys (10, 11, 16–18). The resulting additional (bulky hydrophobic) residue at the N terminus of a substrate is recognized by the ClpS N-recognin, which mediates the delivery of bacterial N-end rule substrates to the proteasome-like ClpAP protease (13–15). Furthermore, in eukaryotes the N-terminal Asp, Glu, and (oxidized) Cys residues are *arginylated* (by R-transferase) before the recognition (through conjugated N-terminal Arg) of thus modified sub-

strates by N-recognins (Fig. 1A). In contrast, N-terminal Asp and Glu in prokaryotes are either stabilizing (unrecognized) residues, for example in *E. coli*, or are destabilizing, *e.g.* in *V. vulnificus*, but through the *leucylation* (not arginylation) of N-terminal Asp or Glu, *i.e.* through their conjugation to Leu by the *bpt*-encoded L<sup>D,E</sup>-transferase, whose specificity differs from that of the *aat*-encoded L/F<sup>K,R</sup>-transferase (2, 12).

The primordial (early) N-end rule presumably comprised a “minimal” set of destabilizing N-terminal residues, *i.e.* the bulky hydrophobic residues Trp, Phe, Tyr, and Leu that are a part of N-end rules in all examined organisms. This set is recognized by prokaryotic N-recognins (ClpS proteins) and by the sequelogous type-2 binding sites of eukaryotic Ub ligases that function as N-recognins (Fig. 1A). The co-option of Arg and Lys into a primordial N-end rule during evolution of eukaryotes involved the emergence of an additional, Arg/Lys/His-specific (type-1) binding site in cognate Ub ligases (Fig. 1, A and B). This elaboration of N-end rule in eukaryotes must have happened after their divergence from prokaryotes, because the Arg/Lys expansion of prokaryotic N-end rules involved an entirely different route, the appearance of the *aat*-encoded, Leu/Phe-conjugating aminoacyl-tRNA-protein transferase (L/F<sup>K,R</sup>-transferase) (2, 12). The apparently independent emergence of the *bpt*-encoded L<sup>D,E</sup>-transferase (which is not sequelogous to the Aat L/F<sup>K,R</sup>-transferase) enabled the Asp/Glu/Cys expansion of prokaryotic N-end rules. Yet again, this evolutionary route was entirely different from the one that emerged in eukaryotes (see above). The two classes of prokaryotic transferases, Aat and Bpt, are largely nonsequelogous and recognize different N-terminal residues, but they do have in common their use of aminoacyl-tRNAs as amino acid donors and their conjugation of a hydrophobic residue, Leu or Phe, to N termini of their respective substrates. This conjugation results in the binding of (thus modified) substrates by the ClpS N-recognin.

Given these constraints on possible evolutionary routes, a parsimonious scenario is that a primordial N-end rule pathway, which targeted substrates via bulky hydrophobic N-terminal residues (but did not recognize, as yet, other N-terminal residues), emerged in a common ancestor of prokaryotes and eukaryotes. Being sensitive to protein folding and recognizing a “topologically” universal determinant (an N-terminal residue is present even in dipeptides), the N-end rule pathway is likely to have appeared early, possibly coevolving with primordial ribosomes during the emergence of translation-endowed organisms. Later expansions of the N-end rule pathway kept specific N-end rules similar in all organisms (presumably because of a selection pressure for N-end rules of certain compositions), but the machinery implementing this pathway evolved divergently in prokaryotes *versus* eukaryotes. In particular, Ub ligases and ubiquitylation/deubiquitylation emerged (or, *alternatively*, were retained) only in eukaryotes (12, 84). In addition, the task of recognizing additional (basic and acidic) N-terminal residues in later, more elaborate N-end rule pathways was solved quite differently in evolving eukaryotes and prokaryotes, as described above. Moreover and significantly, the evolution of N-end rule E3 Ub ligases (N-recognins) in eukaryotes expanded their repertoire of substrate-binding sites beyond the N-end rule. One example is the third substrate-binding site of *S. cerevisiae* UBR1

that recognizes an internal (non-N-terminal) degron in CUP9 and is designed to be controlled, allosterically, by the occupancy of the other two ("N-end rule") binding sites of UBR1 (see Introduction). A landscape of selective pressures, quasi-neutral mutational drifts, and stochastic fixations of changes (85) that gave rise to these differences between eukaryotic and prokaryotic N-end rule pathways remains to be addressed in detail. This problem is made particularly interesting by the fact that although the functions of the N-end rule pathway in eukaryotes are many and partially understood (see Introduction), the functions of prokaryotic N-end rule pathways are still unknown.

*Acknowledgments*—We thank R. Deshaies and P. Bjorkman (Caltech, Pasadena, CA) for the use of Analyst Assay Detection System and BIAcore in their laboratories; S. W. Stevens and J. Abelson (Caltech) for the AK6967 antibody; and D. G. Myszka (University of Utah, Salt Lake City) for the CLAMP and Scrubber programs. We are grateful to former and current members of the Varshavsky laboratory, especially to C.-S. Hwang, for helpful discussions and comments on the manuscript.

## REFERENCES

- Varshavsky, A. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 12142–12149
- Mogk, A., Schmidt, R., and Bukau, B. (2007) *Trends Cell Biol.* **17**, 165–172
- Tasaki, T., and Kwon, Y. T. (2007) *Trends Biochem. Sci.* **32**, 520–528
- Hu, R.-G., Wang, H., Xia, Z., and Varshavsky, A. (2008) *Proc. Natl. Acad. Sci. U. S. A.* **105**, 76–81
- Hu, R.-G., Brower, C. S., Wang, H., Davydov, I. V., Sheng, J., Zhou, J., Kwon, Y. T., and Varshavsky, A. (2006) *J. Biol. Chem.* **281**, 32559–32573
- Hu, R.-G., Sheng, J., Xin, Q., Xu, Z., Takahashi, T. T., and Varshavsky, A. (2005) *Nature* **437**, 981–986
- Lee, M. J., Tasaki, T., Moroi, K., An, J. Y., Kimura, S., Davydov, I. V., and Kwon, Y. T. (2005) *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15030–15035
- Du, F., Navarro-Garcia, F., Xia, Z., Tasaki, T., and Varshavsky, A. (2002) *Proc. Natl. Acad. Sci. U. S. A.* **99**, 14110–14115
- Xie, Y., and Varshavsky, A. (1999) *EMBO J.* **18**, 6832–6844
- Tobias, J. W., Shrader, T. E., Rocap, G., and Varshavsky, A. (1991) *Science* **254**, 1374–1377
- Shrader, T. E., Tobias, J. W., and Varshavsky, A. (1993) *J. Bacteriol.* **175**, 4364–4374
- Graciet, E., Hu, R. G., Piatkov, K., Rhee, J. H., Schwarz, E. M., and Varshavsky, A. (2006) *Proc. Natl. Acad. Sci. U. S. A.* **103**, 3078–3083
- Erbse, A., Schmidt, R., Bornemann, T., Schneider-Mergener, J., Mogk, A., Zahn, R., Dougan, D. A., and Bukau, B. (2005) *Nature* **439**, 753–756
- Wang, K. H., Sauer, R. T., and Baker, T. A. (2007) *Genes Dev.* **15**, 403–408
- Hou, J. Y., Sauer, R. T., and Baker, T. A. (2008) *Nat. Struct. Mol. Biol.* **15**, 288–294
- Suto, K., Shimizu, Y., Watanabe, K., Ueda, T., Fukai, S., Nureki, O., and Tomita, K. (2006) *EMBO J.* **25**, 5942–5950
- Watanabe, K., Toh, Y., Suto, K., Shimizu, Y., Oka, N., Wada, T., and Tomita, K. (2007) *Nature* **449**, 867–871
- Dong, X., Kato-Murayama, M., Muramatsu, T., Mori, H., Shirouzu, M., Bessho, Y., and Yokoyama, S. (2007) *Protein Sci.* **16**, 528–534
- Bachmair, A., and Varshavsky, A. (1989) *Cell* **56**, 1019–1032
- Johnson, E. S., Gonda, D. K., and Varshavsky, A. (1990) *Nature* **346**, 287–291
- Suzuki, T., and Varshavsky, A. (1999) *EMBO J.* **18**, 6017–6026
- Prakash, S., Tian, L., Ratliff, K. S., Lehotzky, R. E., and Matouschek, A. (2004) *Nat. Struct. Mol. Biol.* **11**, 830–837
- Inobe, T., and Matouschek, A. (2008) *Curr. Opin. Struct. Biol.* **18**, 43–51
- Baker, R. T., and Varshavsky, A. (1995) *J. Biol. Chem.* **270**, 12065–12074
- Kwon, Y. T., Balogh, S. A., Davydov, I. V., Kashina, A. S., Yoon, J. K., Xie, Y., Gaur, A., Hyde, L., Denenberg, V. H., and Varshavsky, A. (2000) *Mol. Cell Biol.* **20**, 4135–4148
- Kwon, Y. T., Kashina, A. S., and Varshavsky, A. (1999) *Mol. Cell Biol.* **19**, 182–193
- Kwon, Y. T., Kashina, A. S., Davydov, I. V., Hu, R.-G., An, J. Y., Seo, J. W., Du, F., and Varshavsky, A. (2002) *Science* **297**, 96–99
- Gonda, D. K., Bachmair, A., Wüning, I., Tobias, J. W., Lane, W. S., and Varshavsky, A. (1989) *J. Biol. Chem.* **264**, 16700–16712
- Tasaki, T., Sohr, R., Xia, Z., Hellweg, R., Hörtnagl, H., Varshavsky, A., and Kwon, Y. T. (2007) *J. Biol. Chem.* **282**, 18510–18520
- Kwon, Y. T., Xia, Z., Davydov, I. V., Lecker, S. H., and Varshavsky, A. (2001) *Mol. Cell Biol.* **21**, 8007–8021
- Kwon, Y. T., Xia, Z. X., An, J. Y., Tasaki, T., Davydov, I. V., Seo, J. W., Xie, Y., and Varshavsky, A. (2003) *Mol. Cell Biol.* **23**, 8255–8271
- Tasaki, T., Mulder, L. C. F., Iwamatsu, A., Lee, M. J., Davydov, I. V., Varshavsky, A., Muesing, M., and Kwon, Y. T. (2005) *Mol. Cell Biol.* **25**, 7120–7136
- An, J. Y., Seo, J. W., Tasaki, T., Lee, M. J., Varshavsky, A., and Kwon, Y. T. (2006) *Proc. Natl. Acad. Sci. U. S. A.* **103**, 6212–6217
- Stary, S., Yin, X.-J., Potuschak, T., Schlögelhofer, P., Potuschak, T., Nizhynska, V., and Bachmair, A. (2003) *Plant Physiol.* **133**, 1360–1366
- Garzón, M., Eifler, K., Faust, A., Scheel, H., Hofmann, K., Koncz, C., Yephremov, A., and Bachmair, A. (2007) *FEBS Lett.* **581**, 3189–3196
- Siepmann, T. J., Bohnsack, R. N., Tokgoz, Z., Baboshina, O. V., and Haas, A. L. (2003) *J. Biol. Chem.* **278**, 9448–9457
- Kwak, K. S., Zhou, X., Solomon, V., Baracos, V. E., Davis, J., Bannon, A. W., Boyle, W. J., Lacey, D. L., and Han, H. Q. (2004) *Cancer Res.* **64**, 8193–8198
- Varshavsky, A. (2004) *Curr. Biol.* **14**, R181–R183
- Byrd, C., Turner, G. C., and Varshavsky, A. (1998) *EMBO J.* **17**, 269–277
- Turner, G. C., Du, F., and Varshavsky, A. (2000) *Nature* **405**, 579–583
- Alagramam, K., Naider, F., and Becker, J. M. (1995) *Mol. Microbiol.* **15**, 225–234
- Lupas, A. N., and Koretke, K. K. (2003) *J. Struct. Biol.* **141**, 77–83
- Rao, H., Uhlmann, F., Nasmyth, K., and Varshavsky, A. (2001) *Nature* **410**, 955–960
- Ditzel, M., Wilson, R., Tenev, T., Zachariou, A., Paul, A., Deas, E., and Meier, P. (2003) *Nat. Cell Biol.* **5**, 467–473
- Varshavsky, A. (2003) *Nat. Cell Biol.* **5**, 373–376
- Sasaki, T., Kojima, H., Kishimoto, R., Ikeda, A., Kunimoto, H., and Nakajima, K. (2006) *Mol. Cell* **24**, 63–75
- Lloyd, A. G., Ng, Y. S., Muesing, M. A., Simon, V., and Mulder, L. C. (2007) *Virology* **360**, 129–135
- Yoshida, S., Ito, M., Gallis, J., Nishida, I., and Watanabe, A. (2002) *Plant J.* **32**, 129–137
- Zenker, M., Mayerle, J., Lerch, M. M., Tagariello, A., Zerres, K., Durie, P. R., Beier, M., Hülskamp, G., Guzman, C., Rehder, H., Beemer, F. A., Hamel, B., Vanlieferinghen, P., Gershoni-Baruch, R., Vieira, M. W., Domic, M., Auslender, R., Gil-da-Silva-Lopes, V. L., Steinlicht, S., Rauh, R., Shalev, S. A., Thiel, C., Winterpacht, A., Kwon, Y. T., Varshavsky, A., and Reis, A. (2005) *Nat. Genet.* **37**, 1345–1350
- Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Smith, J. A., Seidman, J. G., and Struhl, K. (2006) *Current Protocols in Molecular Biology*, Wiley-Interscience, New York
- Sherman, F. (1991) *Methods Enzymol.* **194**, 3–21
- Ghislain, M., Dohmen, R. J., Levy, F., and Varshavsky, A. (1996) *EMBO J.* **15**, 4884–4899
- Barral, Y., Jentsch, S., and Mann, C. (1995) *Genes Dev.* **9**, 399–409
- Bachmair, A., Finley, D., and Varshavsky, A. (1986) *Science* **234**, 179–186
- Varshavsky, A. (2005) *Methods Enzymol.* **399**, 777–799
- Johnson, E. S., Ma, P. C., Ota, I. M., and Varshavsky, A. (1995) *J. Biol. Chem.* **270**, 17442–17456
- Lévy, F., Johnson, N., Rüménapf, T., and Varshavsky, A. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 4907–4912
- Sikorski, R. S., and Hieter, P. (1989) *Genetics* **122**, 19–27
- Gietz, R. D., and Sugino, A. (1988) *Gene (Amst.)* **74**, 527–534
- Del Tito, B. J., Jr., Ward, J. M., Hodgson, J., Gershater, C. J., Edwards, H., Wysocki, L. A., Watson, F. A., Sathe, G., and Kane, J. F. (1995) *J. Bacteriol.* **177**, 7086–7091
- Stevens, S. W. (2000) *Methods Enzymol.* **318**, 385–398
- deGroot, R. J., Rüménapf, T., Kuhn, R. J., and Strauss, J. H. (1991) *Proc.*

## UBR1 Ubiquitin Ligase

- Natl. Acad. Sci. U. S. A.* **88**, 8967–8971
63. Seeliger, M. A., Breward, S. E., Friedler, A., Schon, O., and Itzhaki, L. (2003) *Nat. Struct. Biol.* **10**, 718–724
64. Moore, J. M. R., Galicia, S. J., McReynolds, A. C., Nguyen, N. H., Scanlan, T. S., and Guy, R. K. (2004) *J. Biol. Chem.* **279**, 27584–27590
65. Myszka, D. G., and Morton, T. A. (1998) *Trends Biochem. Sci.* **23**, 149–150
66. Morton, T. A., and Myszka, D. G. (1998) *Methods Enzymol.* **295**, 268–294
67. Du, F. (2001) *Allosteric Activation of the Ubiquitin Ligase UBR1 by Short Peptides: Molecular Mechanisms and Physiological Functions*. Ph.D. thesis, California Institute of Technology, Pasadena, CA
68. Feldman, R. M., Correll, C. C., Kaplan, K. B., and Deshaies, R. J. (1997) *Cell* **91**, 221–230
69. Baker, R. T., and Varshavsky, A. (1991) *Proc. Natl. Acad. Sci. U. S. A.* **87**, 2374–2378
70. Bartel, B., Wüning, L., and Varshavsky, A. (1990) *EMBO J.* **9**, 3179–3189
71. Halaris, A., and Plietz, J. (2007) *CNS Drugs* **21**, 885–900
72. Van Regenmortel, M. H. (2003) *Dev. Biol.* **112**, 141–151
73. Maeda, H., Sahara, H., Mori, Y., Torigo, T., Kamiguchi, K., Tamura, Y., Tamura, Y., Hirata, K., and Sato, N. (2007) *J. Biol. Chem.* **282**, 26956–26962
74. Jarvis, T. C., Ring, D. M., Daube, S. S., and von Hippel, P. H. (1990) *J. Biol. Chem.* **265**, 15160–15167
75. Ellis, R. J., and Minton, A. P. (2003) *Nature* **425**, 27–28
76. Minton, A. P. (2001) *J. Biol. Chem.* **276**, 10577–10580
77. Chuang, S. M., Chen, L., Lambertson, D., Anand, M., Kinzy, T. G., and Madura, K. (2005) *Mol. Cell. Biol.* **25**, 403–413
78. Redd, M. J., Arnaud, M. B., and Johnson, A. D. (1997) *J. Biol. Chem.* **272**, 11193–11197
79. Malavé, T. M., and Dent, S. Y. (2006) *Biochem. Cell Biol.* **84**, 437–443
80. Smith, R. L., and Johnson, A. D. (2000) *Trends Biochem. Sci.* **25**, 325–330
81. Xie, Y., and Varshavsky, A. (2000) *Proc. Natl. Acad. Sci. U. S. A.* **97**, 2497–2502
82. Xie, Y., and Varshavsky, A. (2001) *Proc. Natl. Acad. Sci. U. S. A.* **98**, 3056–3061
83. Ju, D., Xu, H., Wang, X., and Xie, Y. (2007) *Biochim. Biophys. Acta* **1773**, 1672–1680
84. Catic, A., Sun, Z. Y., Ratner, D. M., Misaghi, S., Spooner, E., Samuelson, J., Wagner, G., and Ploegh, H. L. (2007) *EMBO J.* **26**, 3474–3483
85. Lynch, M. (2007) *The Origins of Genome Architecture*, Sinauer Associates, Inc., Sunderland, MA
86. Uhlmann, F., Lottspeich, F., and Nasmyth, K. (1999) *Nature* **400**, 37–42